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Abstract
Biomolecules are emerging as the most important source of new therapeutic compounds. Commonly these
molecules are fairly large and unstable in biological environment. Furthermore, the target sites are often located
inside cells and specialized tissues. Another drug group of increasing importance are cancer medicines. Serious
adverse effects are common with these drugs, because they target and destroy tumors that in many ways
resemble healthy tissue. All of these challenges may be solved by sophisticated drug delivery systems that
protect the active ingredient, reduce the adverse effects, distribute the drug preferentially to the target tissue,
and enable efficient drug release inside the diseased cells. Nanoparticle based systems, including liposomes,
have become the most studied method of biologics delivery. They increase drug stability in blood circulation and
facilitates drug accumulation at the target site. However, often the amount of drug released remains insufficient.
Lately, several stimuli-responsive nanoparticles have been developed for better control of the drug release.
Among these are light triggered liposomes, which are the focus of this work.
The main aim during this thesis work was to develop liposomes as a robust and highly controllable platform for
delivery and release of various drug compounds for specific target sites. New manufacturing methods for
liposomal size control were explored and several light triggered liposomal formulations were designed. Detailed
characterization was carried out in order to understand the mechanisms behind the observed drug release. The
final goal was to achieve safe and efficient stimuli-responsive liposomes that have several benefits over currently
commonly used nanoparticle based drug carriers.
Liposomes consist of spherical bilayer forming lipids, phospholipids and sometimes additional stabilizers, such as
cholesterol. The liposomes in this thesis were made with different manufacturing processes, among which the
most common was the thin film hydration method. The size of the formed liposomes was reduced by extrusion,
sonication or high pressure microfluidization. Light triggered release of cargo from the liposomes was achieved
by encapsulating gold nanoparticles (AuNP) or indocyanine green (ICG), that convert light energy into heat. The
produced heat affects the thermosensitive bilayer of the liposomes, making it more permeable for the drug
molecules. The fluidity of the bilayer was analyzed to determine the optimal phospholipid composition. The size
of the liposomes was measured by dynamic light scattering to evaluate the size reduction and uniformity. The
stability of the different formulations was evaluated and compared with each other. Fluorescent molecules were
used as model drug compounds to study the release properties of the liposomes in controlled in vitro and cell
experiments.
The microfluidizer was capable of producing small (around 50 nm) liposomes that distributed to retinal pigment
epithelium after topical administration on rat eyes. Larger liposomes remained in the choroidal vessels and did
not reach the target site. Liposomes with gold nanoparticles were developed for light triggered drug release. The
liposomal formulation utilized pH- and thermosensitivity to pinpoint the release of cargo within the target cells
upon visual or near infrared (NIR) light activation. The light absorbance of the AuNPs depend on their size. Hence,
the total  diameter of these liposomes was rather large (> 150 nm). ICG was used as an alternative triggering
material for the AuNPs to reduce the total size of the drug carrier down to less than 40 nm. These ICG-liposomes
were shown to be highly efficient in completely releasing small compounds as well as macromolecules within 15
seconds upon NIR light irradiation, while still remaining stable during storage. The light-to-heat conversion of
AuNPs and ICG was evaluated by two nanothermoprobes, i.e. laurdan and cadmium selenide quantum dots (CdSe
QD). The light signals used for triggering the drug release and the liposomes encapsulating either AuNPs or ICG
were found to be very well tolerated by cells in viability experiments.
In this work, a large portfolio of methods and formulations was developed. By combining these properties into
a single drug delivery system, efficient protection of the cargo and the healthy tissue, distribution to challenging
target sites, controlled spatial and temporal drug release can be achieved. The next steps in this work involve
evaluation of the optimized carrier with applicable disease models, analysis of the in vivo pharmacokinetics and
more profound toxicological experiments. Even though many challenges remains to be solved, the beneficial
qualities of the light triggered liposomes show great potential for treatment of posterior eye conditions, cancer
and other diseases lacking in therapeutic efficacy.
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11. Introduction
As the expected life span of populations continues to increase, cancer has become one of the most prevalent
causes of death (Figure 1) in affluent countries (WHO 2014). Many active molecules for cancer treatment are
large biopharmaceutics or have severe adverse effects in case of small molecular compounds. The elderly
population has also increased incidence of ocular diseases (Figure 1). Extensive surveys estimated in 2010
that there were almost 300 million visually impaired and 40 million blind people in the world (Pascolini and
Mariotti 2012). More than 50% of the ophthalmic patients are older than 50 years and among elderly Finnish
people (> 65 years) the incidences of cataract (34%), glaucoma (13%), age-related maculopathy (12%) and
diabetic retinopathy (2%) are relatively high (Laitinen, et al. 2010).
Development of new efficient and safe drugs has become difficult and expensive. Typical cost to develop new
drug is about 1 billion euros. Currently, about 1/3 of the new accepted medicines are proteins and the
importance of other biologicals is also increasing. Even though the pharmacologic efficacy of the compounds
may be excellent,  they permeate only  poorly  to  the sites  of  action.  Also,  many small  molecules  that  are
developed in the screening projects have poor solubility, limited tissue penetration or short half-life in vivo.
Thus, drug delivery is one of the most critical challenges of current drug research.
Carefully designed drug delivery systems (DDS) are needed to improve drug access to the tumors in cancer
treatment. Successful targeted delivery of drugs to the tumors should lead to effective treatment at reduced
drug doses thereby improving the drug safety. Ocular drug delivery is also challenging. Especially the retinal
diseases cause severe visual impairment and blindness, but the retinal drug delivery methods are sub-optimal
in  terms  of  efficacy,  safety  and  patient  comfort  (Urtti  2006).  Development  of  more  sophisticated  drug
delivery systems may lead to more effective and safer drug treatment and improved quality of patients’ lives.
Figure 1. Left: The top 10 causes of deaths in wealthy countries in 2012 (WHO 2014). Right: The percentage of population with various
eye diseases in Finland (Laitinen, et al. 2010). The groups were divided by age to 30 – 64 years old people (blue bars) and people of
65 years and older (orange bars). COPD = chronic obstructive pulmonary disease, ARM = age-related maculopathy, DR = diabetic
retinopathy.
Nanoparticles have shown promise as drug delivery systems. Their ability to encapsulate and stabilize various
therapeutic compounds and highly modifiable surface chemistry for active targeting makes them a robust
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2delivery method. Nanoparticles have sizes ranging from a few nanometers to hundreds of nanometers. They
can be produced from various materials, such as polymers, lipids, peptides, metals, oligonucleotides, and
their combinations. Liposomes are nanoparticles formed from lipid bilayers. They were originally introduced
already in the 1960’s (Bangham, et al. 1965) and since then various modifications have been published. The
liposomes are efficient, safe and versatile drug carriers (Torchilin 2005; Torchilin 2012). Both, hydrophilic and
lipophilic cargoes can be packed into liposomes. Furthermore, the liposomal surface can be modified with
targeting ligands for selective accumulation to the target cells. Drug release from the liposomes has been
controlled in many ways, also using different triggering signals for induction of the release. The stimulus for
drug release can be endogenous (e.g. intracellular local pH) or external factor (e.g. ultrasound, light) (Mura,
et al. 2013). The external signal offers possibility to control both time and location of drug release from the
liposomes. Light as a triggering signal would allow localized drug release with high precision laser
technologies.
This  study  aimed  to  generate  technologies  for  light  triggered  drug  release  from  the  liposomes.   Such
liposomes might be useful tools for drug delivery in ophthalmology, oncology and possibly other fields of
medicine. We also explored the retinal drug delivery from liposome eye drops. Overall, these studies included
both physicochemical and biological studies on liposomal drug delivery.
32. Review of literature
2.1.Liposomes as a drug delivery system
Liposomes have been widely studied for the delivery of various drugs. A brief overview of liposomal structure
and its modifications is given in this chapter. Additionally, the general pharmacokinetics and drug release,
including triggering options, are covered. Liposomes in ocular drug delivery and light triggered drug release
are discussed in separate chapters.
2.1.1.  Structure and preparation
Liposomes are small round particles consisting of lipid bilayers surrounding an aqueous internal space
(Bangham, et al. 1965). The main component of liposomes is the phospholipid bilayer that separates the
aqueous core from the external solvent (Figure 2). The phospholipid structure includes a hydrophilic group,
typically phosphatidylcholine (PC) or phosphatidylethanoamine (PE), and one or two hydrophobic alkyl chains.
Depending  on  the  preparation  method  the  liposomes  self-assemble  and  form  spherical  vesicles  with
diameters ranging from 40 nm to a few micrometers. Only the polar hydrophilic groups are in contact with
the external and internal aqueous solutions forming a bilayer with thickness of about 4-7 nm (Balgavý, et al.
2001). Liposomes are roughly categorized by their size and lamellarity. Small unilamellar vesicles (SUV) have
one bilayer and diameter less than 200 nm, large unilamellar vesicles (LUV) also have one bilayer, but their
diameter is in the range of 200 to 1000 nm. Multilamellar vesicles (MLV) have several bilayers contained in
larger liposomes with a diameter ranging from 500 nm to several µm and often have high polydispersity.
Figure 2. Schematics of liposomes, the phospholipid bilayer and the molecular structure of a DSPC phospholipid.
The properties of liposomes are defined by the phospholipids in the bilayer. Firstly, the hydrophilic head
group of  phospholipids  is  usually  neutral  in  net  charge,  but  actually  zwitter  ionic  (e.g.  PC and PE).  Some
liposomes may contain lipids with charged head groups, like anionic phosphatidylglycerol (PG) and cationic
trimethylammonium propane (TAP). Secondly, the length and saturation of the hydrophobic alkyl chains
4affect the rigidity and the permeability of the bilayer (Clejan, et al. 1979). Most liposomes have a specific
phase transition temperature (Tm)  for  a  change from a more rigid  gel  phase to  a  more permeable  liquid
crystalline phase. With longer hydrocarbon chain length, van der Waals interactions become stronger
requiring more energy to disrupt the phospholipid, leading to higher Tm. On the other hand, unsaturation of
the hydrocarbon chain causes a bend that disrupts the phospholipid packing and lowers the phase transition
temperature. The hydrophilic head groups also have a small effect on Tm as PE lipids have higher Tm values
than PC lipids with identical hydrocarbon chains. Cholesterol is commonly added to the bilayer to increase
the stability of liposomes (Kirby, et al. 1980; Ulrich 2002). Cholesterol is located in the free space between
the alkyl chains and it increases bilayer rigidity and decreases lateral diffusion in the lipid bilayer.
Ever since their discovery in the 1960’s (Bangham, et al. 1965), the liposomes have been studied intensively
as a drug carrier (Sharma and Sharma 1997; Torchilin 2012). Liposomes can protect the drug from the
degrading factors in the body and they may also protect the body from the adverse drug effects. Liposomes
are biocompatible, because their structure mimics the lipid bilayers found in the body. This enables drug
delivery with relatively low immune response and toxicity. Furthermore, liposomes are a robust nanocarrier
with high loading capacity (Ulrich 2002). Hydrophilic drugs are encapsulated in the aqueous core of the
liposomes, whereas the lipophilic drugs may be embedded into the lipid bilayer. Additionally, the large
aqueous core offers possibilities to encapsulate small nanoparticles or other agents in the liposomes. The
charge of the anionic or cationic liposomes can be used to actively encapsulate drug compounds with
opposite electric charge (Ulrich 2002). Liposomes may extend the half-life of the drug in blood circulation
and improve their delivery to target tissues and cells. The liposomes accumulate especially in the liver and
the spleen (Litzinger, et al. 1994), which may be undesirable in some cases. The size and surface properties
of liposomes can be easily modified by careful selection of components and preparation methods. Due to
their versatility, liposomes became the first nanocarriers that were approved for clinical use by the Food and
Drug Administration (FDA) in 1995. The products include, for example doxorubicin (Doxil) and amphotericin
B liposomes (Barenholz 2012).
Liposomes are commonly prepared by mixing the phospholipids in organic solvent (e.g. chloroform) followed
by  solvent  evaporation  and  the  formation  of  a  thin  lipid  film  in  a  vial  (Figure  3  A)  (Szoka  Jr  and
Papahadjopoulos 1980; Ulrich 2002). The lipid film is subsequently hydrated by a buffer solution that is
heated above the Tm of the lipids consequently forming a polydisperse mixture of MLVs. The MLVs can be
further processed by sonication, membrane extrusion, homogenization or other methods, to form
unilamellar  vesicles  of  desired  size.  Other  preparation  methods  include  reverse  phase  evaporation  and
microfluidic processes (Barnadas-Rodrıǵuez and Sabés 2001; Paasonen, et al. 2010; Talsma, et al. 1989).
Sonication and membrane extrusion are the most common methods of liposomal size control. In sonication,
the  liposome  sample  vial  is  placed  in  a  bath  sonicator  or  a  probe  sonicator  is  inserted  into  the  sample.
Ultrasonic sound energy causes size reduction of the liposomes (De Kruijff, et al. 1975), but the sonicated
liposomes are polydisperse. The extrusion method, on the other hand, allows preparation of liposomes with
defined size. MLVs are pushed through a polycarbonate membrane with a precise pore size at temperature
above the Tm of the liposome formulation to ensure fluidity of the bilayer (Olson, et al. 1979). After extrusion,
the sample is cooled below the Tm to stabilize the structure. High-pressure homogenization, or
microfluidization, reduces the liposomal size by pushing the sample liquid through narrow micro channels at
very high pressure (Barnadas-Rodrıǵuez and Sabés 2001; Talsma, et al. 1989). The shear forces of the liquid
flow as well as particle collisions to the chamber walls and to each other break the larger particles to smaller
size. By controlling the pressure, temperature and passage times, large volumes of a monodisperse liposomes
can be produced.
5In reverse phase evaporation (Szoka and Papahadjopoulos 1978), the lipids are first dissolved in an organic
solvent and an aqueous solution is mixed with the organic phase to form a water-in-oil emulsion. The organic
solvent is gradually and completely evaporated to form the liposomes in an aqueous solvent. The method
can increase the loading efficiency compared to the thin film hydration method, particularly for hydrophilic
drugs. Microfluidic methods, not to be confused with microfluidization or high-pressure homogenization,
offers a straightforward way to produce liposomes without additional size control steps (Jahn, et al. 2007;
Jahn, et al. 2008). In this method, a continuous flow of two aqueous streams and a separating organic solvent
including the phospholipids are mixed in narrow channels (Figure 3 B). The liposomes are formed by
evaporation  of  the  organic  solvent,  thus  bringing  the  two  lipid  monolayers  of  the  water-oil  interfaces
together. The benefits of the microfluidic process are high encapsulation efficiency by isolation of the inner
phase and the possibility for continuous preparation of large sample volumes.
Figure 3. A: Liposome preparation by thin film hydration method. B: Schematic of microfluidic liposome manufacturing. Modified
from (Calle, et al. 2015; Kim, et al. 2011).
2.1.2.  Administration routes and distribution
Intestinal lipases render per oral delivery impossible for most types of liposomes. Some success have been
achieved with polymer coated liposomes (Takeuchi, et al. 2005a; Takeuchi, et al. 2005b), but the oral delivery
of liposomes is a marginal field. Liposomes can be administrated via other routes, for instance topically to
the skin or eyes, as injections into the blood circulation or vitreous cavity, and inhalation to the respiratory
tract. These application routes have distinct advantages and challenges. Delivery of liposomes to the skin is
very simple and non-invasive, and thus pleasant for the patients, but the tightly layered stratum corneum
prevents the permeation of intact liposomes through the skin. Stratum corneum barrier can be circumvented
to some extent by trafficking liposomes through the hair follicles and sweat glands (du Plessis, et al. 1994).
6The surface area of these routes is only < 0.01% of the total surface area of the skin and thus this approach
is suitable only for localized delivery in some dermal conditions. Drug permeation across the skin can be
enhanced with liposomes if they are highly flexible and fuse with the stratum corneum (Kirjavainen, et al.
1996). Alternatively, the liposomes can be applied through the skin with iontophoresis (Essa, et al. 2002).
Tissue barriers of the cornea and conjunctiva limit drug delivery to the eye after topical instillation as eye
drops (Urtti 2006). Also, the short residence time of the drug on the ocular surface limits bioavailability to
less than 5% (Urtti 2006). Nevertheless, some progress have lately been made in topical liposome delivery to
the eyes and targets in the anterior and posterior segment of the eye have been reached. This is discussed
in more detail in chapter 2.2.
Administration to the nasal cavity or the lungs may offer interesting opportunities for the use of liposome
technology. The liposomes can be prepared for inhalation products using spray drying (Mansour, et al. 2009).
The liposomal diameter must be carefully controlled, since the deposition of inhaled particles in the
respiratory tract depends on the size of the inhaled particles (Gill, et al. 2007). Particles larger than 15 µm
will be retained in the throat and swallowed. For example, localized immune system treatment and insulin
delivery can be achieved with liposomal delivery to the respiratory tract (Huang and Wang, 2006;Khatri et al.,
2008).
In most studies, the liposomes are given as injections (e.g. intravenous, subcutaneous). In these cases, the
tissue barriers are by-passed and the delivery to the site of injection is controlled (Torchilin 2005). However,
liposomes must get across the tissue barriers to reach the extravascular sites. In some cases (e.g. intravitreal
injection), the invasive drug delivery sets limits to the acceptable duration of drug action (Del Amo and Urtti
2008). Intravenous injections enable rapid dosage to the systemic blood circulation and fast distribution to
easily accessible tissues (Moghimi and Szebeni 2003; Torchilin 2005). Subcutaneous injections on the other
hand can be used for prolonged local effect or preferable targeting of the lymphatic system (Oussoren, et al.
1997). Liposomes larger than 100 nm are mostly retained at the injection site whereas small liposomes (40-
70 nm) are distributed to the lymphatic system and blood circulation.
2.1.3.  Elimination, surface modifications and targeting
Despite the advantages of liposomes (e.g. safety and biocompatibility), their main drawbacks as nanocarriers
are plasma interactions that modify their elimination (Koo, et al.  2005). When liposomes reach the blood
circulation, selective serum opsonins (e.g. the complement system) bind to their surface (Harashima, et al.
1994; Moghimi and Patel 1989). The binding depends on the size and the lipid composition of the liposomes.
Mononuclear  phagocyte  system  (MPS)  recognizes  the  opsonized  liposomes  and  removes  them  from  the
bloodstream.  It  is  generally  thought  that  large liposomes are  eliminated from the blood circulation more
quickly  than  smaller  liposomes  (Senior  and  Gregoriadis  1982)  and  negatively  charged  liposomes  have  a
shorter  half-life  in  the  bloodstream  than  neutral  liposomes  (Chonn,  et  al.  1992),  but  this  view  has  been
contested  by  some  reports  (Immordino,  et  al.  2006).  In  any  case,  the  reticulo-endothelial  system  (RES),
primarily in the liver and spleen, removes the uncoated liposomes efficiently from the systemic circulation
within a few hours.
The current state-of-the-art for liposomes with longer circulation times consist of polyethylene glycol (PEG)
or other polymer coating that, sterically protects the liposomes from opsonisation (Allen, et al. 2002). The
detailed mechanism of the enhanced stability of PEG liposomes is not fully understood. Flexible and
hydrophilic PEG covers the liposomal surface even at relatively low molar amounts. The sterically stabilized
liposomes show improved accumulation in the tumors by enhanced permeability and retention (EPR) effect
(Chonn and Cullis 1998). The tumor tissue stimulates a rapid angiogenesis leading to abnormally leaky blood
vessels.  Furthermore,  the  tumor  tissue  often  lacks  the  normal  lymphatic  drainage.  This  causes  the
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render  the  liposomes  completely  ‘invisible’  to  the  MPS  (Moghimi  and  Szebeni  2003).  The  PEGylated
liposomes have also been shown to activate the defense mechanisms through the complement system.
Eventually PEG liposomes are eliminated by the liver and spleen (Allen, et al. 1995). Their retention time in
the systemic blood circulation is approximately 24-48 hours.
The liposome surface can be further modified with ligands, such as antibodies, peptides and other molecules
that recognize and bind to the target cells (Park 2002). The active targeting enables preferential accumulation
in pathological tissues in comparison to the healthy tissues thereby protecting the patient from adverse drug
reactions and enhancing bioavailability. The targeting ligands can be bound covalently to the liposome
surface or tethered at the end of the PEG chain (Maruyama, et al. 1997). Cancer cell targeting with antibodies,
transferrin, folate and other ligands has especially been widely studied (Lee and Huang 1996; Noble, et al.
2014; Torchilin 2005). In principle, the PEG tethered ligand should be readily available for binding at the
target cell surface, but in practice the ligand may be masked within the PEG layer (Lehtinen, et al. 2012; Noble,
et al. 2014).
Cationic lipids and polymers have been used to efficiently encapsulate DNA, mRNA, siRNA, miRNA and
various oligonucleotides into liposomes (Behr, et al. 1989; Felgner, et al. 1987). These can be used to deliver
genes or alter the cellular functions. Viral methods of transfection are more effective than the non-viral
systems, but cationic liposomes are easy to prepare, they have low immunogenicity and they are relative
inexpensive to produce. Anionic liposomes are less commonly used, but they have also been tested for gene
delivery (Lee and Huang 1996; Patil, et al. 2004).
Versatile liposomes allow sophisticated formulation design (Figure 4) to tackle difficult therapeutic
challenges. Some restraint should be used to avoid design of too complicated drug delivery systems, as it
may reduce the biological robustness, be impossible to scale-up, or lead to economic constraints for an actual
commercial drug use.
Figure 4. Schematic of a super multifunctional liposome with protective polymer (A), polymer tethered targeting ligand (B), diagnostic
label compound (C), charged lipids (D), complexed DNA (E), stimuli-responsive lipids (F), stimuli sensitive polymer (G), cell penetrating
peptide (H), viral structure (I), hydrophobic drug (J), hydrophilic drug (K), magnetic compound for targeting (L) and metal nanoparticle
for triggered release (M). Modified from (Torchilin 2005).
82.1.4.  Cellular uptake
Like most nanoparticles, liposomes are most commonly internalized into the cells through endocytosis
pathways, although several other uptake paths have been suggested (Figure 5). The capacity and speed of
cellular uptake varies greatly depending on the cell type. Phagocytosing cells are the most efficient in the
cellular uptake of liposomes. Targeting to binding sites on the cellular plasma membrane can increase the
uptake and make the liposomes more selective (Torchilin 2005). Endocytosis mechanisms are complex
phenomena  that  are  energy  dependent  and  consist  of  several  pathways.  Uptake  of  100  –  200  nm  sized
liposomes is subjected to clathin-dependent mechanisms, whereas small 40 nm liposomes are endocytosed
via a dynamin-dependent pathway and 70 nm liposomes are taken up by both mechanisms (Andar, et al.
2014). Large particles (> 1 µm) are taken up by micropinocytosis or phagocytosis. Often the endocytosis leads
the cargo into lysosomes that may break down the liposomes and release the drug cargo by enzymatic activity
and acidic environment (Ulrich 2002). Some drugs may tolerate the lysosomal conditions, but more sensitive
compounds should escape from the endosomes before trafficking to the lysosomes and degradation.
Figure 5. Interactions of liposomes with cells: specific (a) or non-specific (b) attachment to the cell surface, fusion with the cell
membrane (c), drug release near the target cell (d), transfer of lipids with the cell membrane (e), endocytosis (f), delivery into the
lysosome (g) and destabilization of the endosomal wall and cytosolic drug release (h). Modified from (Torchilin 2005).
2.1.5.  Drug release from liposomes
Passive diffusion is the simplest form of drug release from liposomes. This process is driven by the
concentration gradient between the liposome core and outside medium. The lipid bilayer properties (i.e.
rigidity, charge) control the rate of passive drug release (Szoka Jr and Papahadjopoulos 1980). Reduction in
the alkyl chain length and increased unsaturation render the bilayer more permeable. Likewise, the
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lipophilic compounds can pass through the liposomal bilayers faster than larger molecules that need
disruption in the ordered bilayer for their escape from the liposome (Szoka Jr and Papahadjopoulos 1980).
Charged compounds have notably reduced permeation from the liposomes compared to neutral molecules
of the same size with permeability of 0.054 and 0.227 (10-6 cm/s) for carboxy-fluorescein and fluorescein
sodium, respectively (Flaten, et al. 2006).
Internal triggers of drug release. Even though the correct liposomal size and active targeting may increase
the uptake of the liposomes to the target cells, the therapeutic effect might remain unsatisfactory due to the
inefficient endosomal escape and drug release from the liposomes (Shum, et al. 2001). Endogenous stimuli
can be used to enhance the drug release. These mechanisms are based on the specific changes in the cellular
environment. One of the first applications of triggered release from liposomes was reported in the 1970’s.
The liposomes were formulated with a thermosensitive combination of phospholipids that released the
contents upon hyperthermia (Yatvin, et al. 1978). This is based on specific Tm of the phospholipids at which
point bilayer changes to permeable state and releases the encapsulated drug. Phospholipid bilayer should
remain in the gel state at + 37 °C and converted to fluid state at hyperthermia, for instance in the tumors
(Yatvin, et al. 1978). Cancerous tissue has approximately 2 °C higher temperature than the surrounding
healthy tissue (Goldson 2012). Alternatively, a thermosensitive component, like a leucine zipper, can be
included in the liposome formulation to render it thermosensitive at required temperature range (Al-Ahmady,
et al. 2012). The release may also be triggered by heating the target tissue, but this is obviously limited to the
surface tissues. Hyperthermia affects extracellular and intracellular liposomes in the tissue similarly. This is a
problem in intracellular drug targeting (e.g. DNA and RNA delivery). Also, the operative temperature range
in these approaches is limited and this restricts the selection of suitable lipids.
One  of  the  most  common  methods  for  increased  contents  release  within  the  cells,  is  to  formulate  pH-
sensitive liposomes. After being endocytosed in the stable form, these liposomes break down as a results of
the lower pH inside the endosomes (Chu, et al. 1990; Yatvin, et al. 1980). The increased endosomal release
has been commonly achieved by the incorporation of a pH-sensitive combination of lipids, co-polymers or
orthoesters (Chu, et al. 1990; Sawant, et al. 2012; Zhu, et al. 2000). In addition to pH-sensitive formulations,
enzymatic  degradation  has  been  utilized  as  a  release  mechanism.  Higher  concentrations  of  proteases  in
cancer tissue has been used to enhance drug release from liposomes (Banerjee, et al. 2009). A recent
approach for enhanced cellular uptake and contents release to the cytosol uses viral component modified
liposomes (Bungener, et al. 2002). These cell-penetrating peptides and proteins, such as the transactivating
transcriptional  activator  (TAT),  are  reported  to  enable  delivery  through  micropinocytosis  and  enhanced
endosomal  escape (Koren,  et  al.  2012).  The underlying mechanism is  poorly  known and other  report  has
indicated that the enhanced uptake is not due to the specific structure of the TAT, but rather the cationic
charge of the molecule (Subrizi, et al. 2012).
External triggers of drug release. Exogenous triggering of drug release is an attractive option, because it
allows precise and time dependent control of drug release. As mentioned earlier, thermosensitive liposomes
can be triggered with external heating of the target. The method has been used in cancer research: target
tissue has been heated with hot water pouches, radio oscillators or small microwave devices (Huang, et al.
1994; Kono, et al. 2010). The most sophisticated thermosensitive liposome formulations are stable at body
temperature, but release the contents rapidly after an increase in the temperature over 40 °C (Tagami, et al.
2011). In addition to the temperature, pH and enzymes discussed above, external triggers, such as ultrasound,
magnetic field and light have been explored. Light as an external trigger is discussed in a dedicated chapter
below.
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Ultrasound has been extensively investigated as an approach for triggered drug release from the liposomes.
The method is attractive due to its non-invasive nature and adjustment of tissue penetration by frequency
(Huang 2008). In liposomes, ultrasound causes cavitation in the bilayer enabling the drug release (Schroeder,
et al. 2009). Small air pockets or encapsulated perfluorocarbon nanoemulsion can enhance the cavity
formation and achieve increased sensitivity to ultrasound without causing damage to cellular bilayers. This
method has been used in the treatment of cerebral ischemia, gene delivery and cancer vaccination (Britton,
et al. 2010; Negishi, et al. 2012; Un, et al. 2011). It has been found that ultrasonic signal also causes pore
formation in  the endosomes of  the target  cells  improving endosomal  escape (Omata,  et  al.  2011).  Cavity
formation requires high ultrasound frequencies (> 1 MHz) that should be used with care, because it can heat
the tissues to damaging temperatures within seconds (ter Haar 2007). On the other hand, milder localized
heating and drug release from thermosensitive liposomes can be achieved with low frequency ultrasound
( 20 – 100 kHz) (Huang 2008), but in this case the triggering is more difficult to pinpoint to a small target area.
Magnetic field can be used to guide the liposomes to their targets. This method concentrates the liposomes
in  the  target  tissue.  For  example,  magnetic  Fe3O4 and  Fe2O3 nanocrystals have been encapsulated into
liposomes for this purpose (Plassat, et al. 2011). Magnetism can be used to trigger drug release, because the
magnetic  nanoparticles  produce  heat  via  hysteresis  and  Néel  relaxation  when  they  are  within  a  rapidly
oscillating magnetic field. The heat will trigger the contents release when the bilayer permeability is increased
in the thermosensitive liposomes (Katagiri, et al. 2011; Tai, et al. 2009).
2.2.Drug delivery to eyes
Ocular drug delivery, particularly to the retina, is a difficult challenge (Del Amo and Urtti 2008; Urtti 2006).
The eye is well protected from the surroundings by various barriers and defense mechanisms. The eye is also
at least partially an immune privileged organ. Development of efficient drug delivery systems is vital for
effective therapy to the retina. Several ocular diseases (i.e. age-related macular degeneration (AMD), diabetic
macular edema (DME), proliferative vitreoretinopathy (PVR), posterior uveitis, cytomegalovirus (CMV)
infection and glaucoma) are affecting the posterior parts of the eye, particularly the retina. Therefore,
development of efficient drug delivery to the posterior eye segment is important (Del Amo and Urtti 2008;
Thrimawithana, et al. 2011).
2.2.1.  Structure of the eye
In the context of drug delivery, the eye can be divided into two main parts: anterior and posterior segments.
The anterior segment includes roughly one-third of the eye consisting of cornea, conjunctiva, pupil, aqueous
humor, iris, lens and ciliary body (Figure 6). The posterior segment consists of vitreous humor, retina, choroid,
sclera and optic nerve making up the remaining two-thirds in the back of the eye.
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Figure 6. Schematic presentation of the ocular tissues. Routes of drug administration and distribution (solid arrows), and elimination
(dashed arrows) are shown. Topical permeation route through the cornea (1). Topical permeation route via conjunctiva and sclera to
anterior uvea (2). Drug distribution from ciliary body into the anterior chamber (3). Elimination of drug from the anterior chamber to
Schlemm’s canal (4) and the blood circulation in the anterior uvea (5). Drug distribution from the choroidal blood into the posterior
eye (6). Intravitreal drug delivery (7). Elimination of drug from vitreous to choroidal blood flow via blood-retina barrier (8). Drug
distribution and elimination from the vitreous to the posterior and anterior chamber (9). Image from (Del Amo and Urtti 2008).
2.2.2.  Barriers of drug delivery
The  anterior  segment  of  the  eye,  consisting  of  cornea,  conjunctiva,  anterior  chamber  and  uvea,  is  most
commonly treated with topical eye drops. Although the anterior parts might seem to be easily accessible for
topical drug delivery, several barriers in the eye limit the ocular bioavailability of drugs. Firstly, the lacrimal
fluid flow (induced and normal baseline) on the ocular surface removes the instilled eye drop to the
nasolacrimal duct and nasal cavity, where the drug may absorb into the systemic circulation (Urtti, et al. 1985;
Urtti and Salminen 1993). Secondly, the corneal epithelium limits drug absorption to the anterior chamber
(Maurice and Mishima 1984). The epithelium consists of matured corneal epithelial cells with tight junctions
on the apical surface. Therefore, the drug should have some lipophilicity for adequate permeability across
the cornea (Prausnitz and Noonan 1998). The corneal drug permeability was correlated with the chemical
structure recently (Kidron, et al. 2010). Drug permeability was predicted well with hydrogen bonding capacity
and logD7.4. Conjunctiva has a leakier epithelium compared to the cornea, and its surface area is almost 20
times larger than the cornea (Prausnitz and Noonan 1998). The permeation of hydrophilic and large drug
compounds is therefore significantly better in the conjunctiva than in the cornea suggesting that such
compounds are absorbed into the eye preferably through the conjunctiva and sclera instead of cornea
(Ahmed and Patton 1985). On the other hand, the palpebral conjunctival is a route for direct systemic drug
absorption from the lacrimal fluid, and this factor also limits the ocular bioavailability (Urtti, et al. 1985; Urtti,
et al. 1990). Overall, less than 5% of the initial dose, often less than 1%, is absorbed into the eye after topical
eye drop administration (Maurice and Mishima 1984; Urtti, et al. 1990)
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In analogy with the blood-brain barrier, the blood-ocular barrier protects the eye from the xenobiotics in the
systemic blood circulation. The blood-ocular barrier consists of blood-aqueous barrier in the anterior uvea
and a blood-retina barrier in the posterior segment of the eye (Maurice and Mishima 1984). Drugs may
distribute through these barriers from the systemic circulation to the inner eye. The blood-retina barrier is
further divided to two parts: the retinal capillaries in the neural retina and the retinal pigment epithelium
(RPE). The walls of the retinal capillaries are tight and form a strong barrier against drug permeation. On the
other hand, in the choroid the blood flow is high and the vessels have fenestrated leaky walls (pore size of
about 80 nm) (Guymer, et al. 2004). Thus drugs and small nanoparticles can pass through the choroidal
endothelia to the extravascular space, but further distribution to the retina is limited by the RPE. Tight
junctions and efflux transporters of the RPE cells form a specific barrier against further drug permeation into
the eye (Mannermaa, et al. 2006). Generally, lipophilic molecules permeate the blood-retina barrier more
readily than hydrophilic compounds (Pitkänen, et al. 2005).
2.2.3.  Ocular routes of drug delivery
Topical eye drop instillation on the ocular surface is the most common way of drug administration in ocular
drug treatment. This is due to the relative ease of administration, usually high patient acceptance, and low
cost.  The  drugs  are  absorbed  from  the  lacrimal  fluid  to  the  eye  via  corneal  or  conjunctival  routes.  The
challenges of topical drug delivery include short contact time and tissue barriers that reduce the drug access
the target sites. This can be improved with formulations that have prolonged residence time on the ocular
surface and improved bioavailability (e.g. gels, ointments, inserts). The disease targets for eye drops are in
the  anterior  part  of  the  eye,  because  drug  distribution  to  the  posterior  segment  is  too  low  to  be
therapeutically effective (Urtti 2006). Common topically treated diseases include glaucoma, cataract and
infections of the anterior part (e.g. conjunctivitis).
After systemic administration, the blood-retina barrier limits the drug access to the retina (Maurice and
Mishima  1984;  Vellonen,  et  al.  2015).  Only  a  small  portion  of  total  blood  circulation  goes  through  the
choroidal vessels and thus large doses may be needed for satisfactory therapeutic effect in the retina. This
can lead to adverse effects in other parts of the body.
Direct intravitreal injections and implants bypass most ocular barriers and this route of administration is the
golden standard in the treatment of the ocular posterior segment. The drug is delivered efficiently with a
small needle through the conjunctiva, the sclera and the uvea to the vitreous at pars plana region. Higher
initial drug concentration near the diseased tissue enables smaller drug dose reducing systemic side effects.
On the other hand, the invasive nature of intravitreal injections may reduce patient comfort and it can be
costly  because the drug must  be applied by medical  professionals  (Jonas,  et  al.  2008;  Wu,  et  al.  2008b).
Overall the injection complications are rare during the intravitreal drug treatment (e.g. antibody treatments
for age related macular degeneration). The dosing interval may be prolonged with controlled release systems
(gels, implants).
Subconjunctival and periocular routes are used to treat anterior conditions (e.g. local anesthesia), but these
routes are also interesting options for the treatment of the uvea and the posterior segment of the eye. A
simple injection or drug insert is placed between the conjunctiva and the sclera. Thereafter, drug should
permeate through sclera towards the inner part of the eye. Even though most of the drug absorbs
systemically  from  the  injection  site  (Ranta,  et  al.  2010),  drug  delivery  to  the  posterior  segment  can  be
effective due the high permeability of the sclera, even for macromolecules (Prausnitz and Noonan 1998).
Furthermore, subconjunctival and periocular injections have shown better safety when compared to more
invasive intravitreal injections (Raghava, et al. 2004), although some complications, including intraocular
pressure rise,  strabismus and cataract,  have been reported during periocular  treatments  (Castellarin  and
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Pieramici 2004). In addition to scleral penetration, the drug should pass through the choroid and the RPE for
retinal  treatment.  Drug  removal  to  the  choroidal  blood  flow  an  RPE  barrier  limit  the  retinal  drug
bioavailability (Ranta, et al. 2010).
2.2.4.  Pharmacokinetics of the eye
After topical drug administration, the peak concentration in the aqueous humor is commonly reached in
about 30 minutes. Usually, the drug distributes to the anterior chamber by passive permeation, but the
distribution of some compounds (e.g. acyclovir prodrug) may be enhanced by peptide transporters located
in the cornea (Anand and Mitra 2002). Other potential transporters in the cornea are various amino acid
transporters (Anand, et al. 2004; Ganapathy and Ganapathy 2005). The drug may distribute from the aqueous
humor to the surrounding tissues, for example ciliary body and the iris, where melanin binding may take
place (Salminen, et al. 1984). This binding can act as a prolonged release mechanism that extends the
therapeutic drug effect (e.g. atropine) (Menon, et al. 1989). The drug elimination from the anterior chamber
takes place through aqueous humor flow to the Sclemm’s canal and via drug distribution to the blood
circulation in the anterior uvea. The elimination via aqueous flow has a relatively constant rate and it is
independent of drug properties. On the other hand, elimination through the blood flow depends on the
ability of the drug to permeate through the endothelial vessel walls to the systemic blood circulation. As
lipophilic drugs permeate the cellular barriers more readily, they have faster clearance from the anterior
chamber compared to hydrophilic compounds (Urtti 2006). Frequent dosing is often required in topical ocular
drug treatment.
The pharmacokinetics of drug delivery from the systemic blood flow are not completely understood
(Vellonen,  et  al.  2015).  Hydrophilic  compounds  have  lower  permeation  through  the  cellular  RPE  than
lipophilic drugs (Vellonen, et al. 2015). It is known that the choroidal blood flow plays a major role in drug
clearance from the posterior segment. The flow rate of blood through a choroidal vessel is 6 µL/min (Miura,
et al. 2012) and it is important for the drugs to escape to the extracellular space before being carried away
by the choroidal circulation. The retina has the highest metabolic rate per tissue weight, even higher than
the brain, and thus needs a lot of energy (Winkler 1981). For meeting this energy need, the blood-retina
barrier has many glucose transporters that might be utilized for drug permeation, if the drug can fit the high
specificity of the transporters. The RPE has several efflux transporters, including P-glycoprotein (P-gp) and
multidrug resistant protein (MRP), which limit the permeation of several drugs to the retina (Aukunuru, et al.
2001; Constable, et al. 2006). These efflux transporters have also been found in the cornea (Dey, et al. 2003;
Zhang, et al. 2008).
Distribution of the drug within the vitreous after intravitreal injection is relatively free due to the lack of
major barriers. Drugs distribute rapidly in the vitreous and move towards the retina, but the elimination
though the blood-retina barrier is strongly dependent on compound properties (del Amo, et al. 2015;
Maurice and Mishima 1984) Small lipophilic molecules escape from the vitreous rapidly, half-lives are
typically a few hours (del Amo, et al. 2015).  However, compounds with high molecular weights exceeding 40
kDa retain longer in the vitreous humor due to their lower permeability in the blood ocular barriers (Marmor,
et al. 1985). Thus, their half-lives are many days in the vitreous (Maurice and Mishima 1984). Vitreous does
not limit molecular movement significantly so that even particles up to the size 500 nm can move freely in
the vitreous (Xu, et al. 2013). Vitreous can represent significant barrier for the distribution and elimination
of positively charged compounds (Figure 7). Small molecules are eliminated from the vitreous via blood
ocular barriers and via diffusion from the vitreous to the aqueous humor thereafter to the Schlemm’s canal
(del Amo, et al. 2015). Macromolecules utilize only the anterior elimination route via aqueous humour, since
their permeability in the blood retina barrier is very low (del Amo, et al. 2015; Pitkänen, et al. 2005).
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Figure 7. Freedom  of  movement  of  nano-  and  microparticles  in  bovine  vitreous.  PS  =  polystyrene.  NP  =  nanoparticle.  PEG  =
polyethylene glycol. Image from (Xu, et al. 2013).
Conjunctival blood circulation and lymphatic flow reduces the bioavailability after subconjunctival drug
administration (Ranta and Urtti 2006). On the other hand, the high permeability of the sclera enables efficient
drug distribution (Prausnitz and Noonan 1998), but choroidal blood flow may limit the further permeation to
retina (Ranta, et al. 2010). It has been shown that direct penetration through the sclera is the predominant
pathway for the drug to enter the vitreous after subconjunctival injection and distribution via blood
circulation or diffusion from aqueous chamber to vitreous are minimal (Lee and Robinson 2001). Even though
the drug is distributing through highly vascularized tissues after subconjunctival injection, the systemic
plasma concentrations have reported to be similar with intravitreal injections (Nomoto, et al. 2009).
2.2.5.  Ocular drug delivery systems
As discussed earlier, eye drops are frequently administered and their use results in low ocular bioavailability.
Some enhancement of ocular permeation can be achieved with prodrug approach (Shirasaki 2008), since
prodrugs can improve the solubility, stability, and permeability of the instilled drugs. In addition to simple
eye drops, several other approaches have been used for topical drug delivery to the eye (Table 1).
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Table 1. Examples of ocular drug delivery systems.
DRUG DELIVERY SYSTEM ACTIVE SUBSTANCE EFFECT REFERENCES
OCUSERT CONJUNTIVAL SAC
INSERT
Pilocarpine Greater hypotensive effect than an
ophthalmic solution for 2-4 days with a
single insert. Problems with insert slip outs
from the sac.
(Abrahamson 1975;
Armaly and Rao 1973)
GEL FORMING EYE DROPS Timolol Reduction of dosage frequency. Gel
forming eye drops once a day had the
same hypotensive effect as an ophthalmic
solution applied twice a day.
(Shedden, et al. 2001)
MICROEMULSION Pilocarpine Reduction of dosage frequency. Similar
hypotensive effect with the microemulsion
once or twice a day and an ophthalmic
solution four times a day.
(Garty, et al. 1994;
Naveh, et al. 1994)
NANOSUSPENSION Piroxicam,
cloricromene
Enhanced anti-inflammatory effect
compared to a microsuspension. Improved
stability compared to a simple solution.
(Adibkia, et al. 2007;
Pignatello, et al. 2006)
DRUG INFUSED CONTACT
LENSES
Lidocaine Therapeutic levels of drug release for 3-5
days.
(Gulsen and Chauhan
2004)
Simple intravitreal injections have widely been used for treatment of the posterior segment diseases, for
example age-related macular degeneration. The drug access to the posterior segment is significantly
improved, but the need of repeated and unpleasant injections remains as a problem. Depending on the drug,
half-lives  of  one hour  to  many days  have been reported (del  Amo,  et  al.  2015).  Simple  injection of  drug
solution is applicable only for large molecules with long half-life, wide therapeutic index and high potency.
Otherwise, frequent injections (interval of days) would be needed and this is unacceptable.  Therefore,
prolonged action intravitreal delivery systems have been investigated and developed.
Two decades ago, the first intravitreal implant was launched to the clinical use to prolong the drug exposure
and  enable  stable  concentration  in  the  vitreous  (Vitrasert)  (Dhillon,  et  al.  1998).  Since  then,  several
intravitreal implants have been developed (Table 2). Non-biodegradable (e.g. polyvinyl alcohol, PVA)
controlled release implants may have duration of action of several years, while biodegradable implants have
shorter  duration  of  months,  but  they  do  not  need  to  be  removed  from  the  eye  (Bourges,  et  al.  2006).
Polymeric biodegradable implants often have three phases of drug release: an initial burst, a middle phase
and a final burst release. Newer implants have achieved prolonged and more stable release profiles with near
zero-order drug release kinetics (Kunou, et al.  2000; Yasukawa, et al.  2005). In addition to the prolonged
release, the implants have other benefits, such as reduction of adverse effects, because of lower drug
concentrations without initial peak are maintained throughout the treatment period and less drug is needed
for therapeutic effect. Some implants (for example Medidur) have been formulated into the shape of long
cylinder, which enables injection of the implant instead of surgery which reduces the invasiveness of the
treatment (Lee, et al. 2010). Implants can also be located outside the vitreous in the sclera or subconjunctival
space thus eliminating the need to perforate the sclera or uvea (Lee, et al. 2010). Another option is to inject
a gelifying formulation that is in a liquid state prior the injection, but forms a more rigid gel via a change in
temperature, ionic concentration or pH (Bochot, et al. 1998; Del Amo and Urtti 2008). With this approach,
invasiveness is reduced, but the typical drug release period is shorter than with implants.
16
Table 2. List of intravitreal implants. Modified from (Del Amo and Urtti 2008).
IMPLANT FORMULATION ACTIVE
SUBSTANCE
ADMINISTRATION METHOD PHYSICAL SIZE REFERENCES
VITRASERT
(NON-BIODEGRADABLE)
Ganciclovir Implantation at the pars plana Few
millimeters
(Bourges, et al.
2006; Dhillon, et al.
1998)
RETISERT
(NON-BIODEGRADABLE)
Fluocinolone
acetonide
Implantation at the pars plana 3 x 2 x 5 mm (Jaffe, et al. 2006)
MEDIDUR
(BIODEGRADABLE)
Fluocinolone
acetonide
Intravitreal injection 3.5 x 0.37 mm
cylinder
(Lee, et al. 2010)
POSURDEX
(BIODEGRADABLE)
Dexamethasone Intravitreal injection or through small
incision at the pars plana
Microsized (Kuppermann, et al.
2007)
Drugs can be formulated into micro- or nanoparticles for topical administration or intravitreal injection.
Biodegradable and FDA approved polymers (poly lactic-co-glycolic acid (PLGA), polyethylene glycol,
polylactide) can release drugs up to several months (Moshfeghi and Peyman 2005). The large microparticles
sediment slowly to the bottom of the vitreous while the smaller particles float freely and may cause clouding
of the vitreous. A less invasive method is to inject the particles to the subconjunctival space, but then the
compound must permeate several barriers in order to reach the retinal tissues. Nanoparticles have lately
been of great interest in ocular drug delivery. Their small size enables efficient distribution and their
properties can easily be adjusted by the selection of formulation and surface modification. Furthermore,
nanoparticles can significantly increase the solubility of some poorly soluble drug compounds (Kayser, et al.
2005). Nanoparticles can be built from polymers or lipids forming uniform beads, dendrimers, liposomes or
micelles (Gaudana, et al. 2009). These delivery systems are taken up by phagocytosing cells, such as the RPE
and can be found at the target for as long periods as 4 months (Bourges, et al.  2003). Even more specific
targeting can be achieved by attaching ligands of specific receptors on the surface of the nanoparticles,
especially in the case of dendrimers (Sahoo, et al. 2008). The most sophisticated nanoparticle based drug
carriers  can  be  remotely  monitored  and  the  drug  release  triggered  at  desired  location  and  time  point.
Nanoparticles may function as a controlled release devices for topical drug delivery offering a prolonged
duration (Cavalli, et al. 2002) and enhanced corneal permeation (De Campos, et al. 2003) compared to simple
eye drops. In the case of liposomes, the surface charge plays an important role in the distribution in the eye.
Cationic positively charged liposomes are bound by the negatively charged corneal surface after topical
delivery. This increases the residence time and corneal uptake (Felt, et al. 1999). On the other hand, cationic
particles do not move freely in the vitreous, as discussed earlier. With optimized liposome formulation,
increased permeation into the eye and higher concentration at the target site can be achieved (Lajavardi, et
al. 2007; Nagarsenker, et al. 1999; Shen and Tu 2007).
One interesting avenue for prolonged drug effect is localized production of the therapeutic compound by
encapsulated cells. The cells can be suspended in microcapsules or a gel (Kontturi, et al. 2011; Kontturi, et al.
2015; Wikström, et al. 2008). Optionally, larger implants can also be used to house the drug producing cells
(Sieving, et al. 2006; Thanos, et al. 2004; Uteza, et al. 1999). The encapsulated cells are genetically modified
to produce the protein drug and polymer isolates the cells from the body components. Nutrients and oxygen
diffuse into the device keeping the cells alive and the produced drug and waste compounds are released
outside the device. Treatment periods of several months or even years are possible with such devices.
Iontophoresis offers a non-invasive alternative for increasing the drug permeation into the eye (Parkinson,
et  al.  2003;  Vollmer,  et  al.  2002).  The  method  consists  of  electrical  current  that  drives  ionized  drug
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compounds through the cellular membranes. Iontophoresis can be applied for corneal and scleral drug
trafficking. Trans-scleral route is more preferable, because of less tight barriers and a more direct path to the
posterior segment of the eye. The benefits of iontophoresis are reduced invasiveness compared to injections
and implants, but the drug effect is shorter, and the range of applicable drug compounds is more limited.
Also practical use may be difficult, and there is no targeting of specific cell types.
Microneedles are another alternative for delivering a wider range of drug compounds with very low
invasiveness. The needle is inserted into the sclera and drug substance is injected into a suprachoroidal space
(Jiang, et al. 2007). Different needle lengths and injection pressures affect the distribution in the
suprachoroidal  space  (Patel,  et  al.  2011).  Microneedle  delivery  is  suitable  many  drug  compounds  and
formulations, but it is more invasive as a method than iontophoresis.
2.3.Light triggered drug delivery systems
External triggering of drug release is feasible in the light-accessible organs, such as eye and skin. Light is an
attractive remote triggering method for drug release, because it can be used with great spatial and temporal
control. Furthermore, the parameters (i.e. beam diameter, exposure duration, wavelength and light
intensity) can be adjusted in versatile manner for the specific drug delivery system and target tissue
(Alvarez‐Lorenzo, et al. 2009). This high level of control may allow therapy adjustments according to the
progression of the disease and cyclic changes in the body. Nanocarriers can release their cargos via several
mechanisms upon light triggering, such as surface plasmon absorption and photothermal reaction, light
driven isomerization and oxidation, hydrophobicity changes due to light exposure, photo fragmentation of
polymer backbone and photo driven de-crosslinking (Alvarez‐Lorenzo, et al. 2009; Timko, et al. 2010). The
used materials vary greatly depending on the particular light triggering method. Light triggered DDS can be
roughly divided into single use (i.e. all of the cargo is released upon triggering) or switchable systems (i.e.
drug release can be controlled by turning the triggering light on and off for pulsed release) (Timko, et al.
2010). It should be noted that light triggered DDS is a distinct method from photodynamic therapy, where
light signal causes cell death through localized heating and singlet oxygen release from a photosensitizer
compound (Wilson and Patterson 2008). These systems represent different mechanisms and purpose, not
controlled drug release and delivery.
2.3.1.  Triggering materials
General requirements for light triggered materials are an adequate stability during shelf-life storage and in
vivo, and selective drug release after exposure to irradiation by the ultraviolet (UV), visible or infrared (IR)
range. The light must induce some structural changes in the system that leads to the drug release (Fomina,
et al. 2012). UV and visible light can be used to trigger only superficial tissues, because the wavelengths under
700 nm do not reach tissues deeper than 1 cm (Weissleder and Ntziachristos 2003). On the other hand, near-
infrared (NIR) light (700 – 900 nm) has minimal absorbance to hemoglobin (abs. < 650 nm), water (abs. > 900
nm) and lipids, and it can penetrate to the tissues several centimeters depending on the light intensity
(Weissleder 2001). In addition to the efficient release mechanisms, the materials should be able to carry
drugs. For cellular targeting, the nanosized systems should be amenable for targeting ligand conjugation to
the nanoparticles.
Gold and other metal nanoparticles. NIR wavelengths are preferred for light triggered drug release, due to
deep tissue penetration. Metal nanoparticles can be activated with NIR light as these particles absorb light
and release the light energy as heat energy, and in some cases fluorescence, that arises from the oscillation
of electrons on the nanoparticle surface, i.e. surface plasmon resonance (Jain, et al. 2006). One of the benefits
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of  metal  nanoparticles  is  the tunable  absorbance wavelength that  depends on the size  and shape of  the
particle. Gold is the most commonly used material due to its inertness and availability of various sizes (from
2 nm to over 100 nm) and shapes of nanoparticles (spheres, rods, shells, stars, cages) with distinct reactions
upon light induction (Timko, et al. 2010) (Figure 8).
Figure 8. Transmission electron microscopy (TEM) images of gold nanospheres (A), nanorods (B), nanoshells (C) and nanocubes (D).
Image from (Timko, et al. 2010).
The  most  common  way  to  produce  gold  nanorods  is  by  anisotropic  lengthening  in  the  presence  of  the
cetyltrimethylammonium bromide (CTAB) surfactant (Jana, et al. 2001; Nikoobakht and El-Sayed 2003). The
nanorod is built from a small spherical gold seed and the process is stopped once the desired length is
reached. Nanorods have two light absorption wavelength maximums, a shorter wavelength for the short axis
of the particle and the more useful longer wavelength for the long axis (Huang, et al. 2006). In one example,
a cancer drug, doxorubicin, was bound by thermosensitive DNA helices tethered on the surface of gold
nanorods (Xiao, et al. 2012). Localized heat produced by the nanorods upon light triggering released the drug
from the DDS. In another release method, short laser pulses can break down the nanorods into nanospheres
and simultaneously releasing the contents (Chen, et al. 2006).
Hollow gold nanospheres or nanoshells can be induced with variable absorbance wavelengths (from mid
visual to infrared range) (Timko, et al. 2010). The frequency of surface plasmon resonance is dependent on
the diameters of the inner and outer surfaces of the nanoshells. One study showed encapsulation of
doxorubicin into gold nanospheres and release of the contents upon NIR light triggering, which increased the
anticancer efficacy compared to free doxorubicin (You, et al. 2012). Also triggered macromolecule release,
e.g. DNA and siRNA release, have been achieved with gold nanoshells (Barhoumi, et al. 2009; Braun, et al.
2009). The cargoes were bound to the surface of the nanoshells by linkers that react to the surface plasmon
resonance upon light triggering.
Gold nanocages are among the most complex metal particles. They are porous and hollow cubes with sizes
ranging from 30 nm to 200 nm (Skrabalak,  et  al.  2008).  Gold nanocages  can encapsulate  the drug in  the
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hollow internal space if the cage is coated with hydrophobic thermosensitive polymer (Yavuz, et al. 2009).
When the DDS is irradiated with NIR light, the heat produced by the cage breaks down the polymer layer and
the contents are released. Large compounds, such as enzymes, can be encapsulated and released with the
nanocages.
Polymers. A tight polymer structure can be made more porous by breaking the light sensitive crosslinks (e.g.
o-nitro benzyl) between the polymer backbones (Fomina, et al. 2012; Mura, et al. 2013). For example,
dendrimers can be built around a light sensitive core that breaks the whole structure upon light triggering,
enabling fast release of the contents (Amir, et al. 2003). Most de-couplings of the crosslinks require UV or
short wavelength visible light thereby limiting usefulness of this approach in vivo. Alternatively, photo-
crosslinking  or  photo-polymerization  can  be  used  as  a  drug  release  scheme,  even  though  it  may  seem
counter-intuitive. The crosslinking can be used to shrink parts of the liposome surface, which in turn produces
pores and enables contents release (Regen, et al. 1981). Initial studies utilized UV light, but later visible light
methods  with  specific  sensitizers  have  been  reported  (Fomina,  et  al.  2012).  Crosslinking  and  photo-
polymerization can also be used with polymeric particles where light causes shrinkage of the particle that in
turn forces the drug out of the particle as the internal volume is reduced (Shi, et al. 2008). Light triggering
can also control the fluidity of some gels. This opens up one possibility of injectable solutions that form a gel
in situ (introduced in the chapter 2.2.5). The fluidity of the gel is increased with UV light and a more viscous
gel is formed under visible light (Suzuki, et al. 2006). The method is based on azobenzene crosslinkers that in
trans form make a ladder structure between the polymer chains under visible light. UV light on the other
hand changes the azobenzenes to cis form breaking the ladder structure and reducing viscosity.
Another light induced controlled release method is based on micellar amphiphilic polymers that undergo
light triggered structural changes. Photosensitivity of block copolymers is often achieved by incorporating a
chromophore to the hydrophobic block. In this case, light activation causes a conformational or structural
change in the hydrophilicity balance causing disruption of the micellar form (Zhao 2007). The triggering
wavelength depends on the chromophore and this allows flexibility in design of the DDS (El Halabieh, et al.
2004). Later variations of this method enabled reversible change between amphiphilicity and hydrophilicity,
where UV light produces hydrophilic block copolymers and visible light reverted them back to an amphiphilic
state. This effect can be achieved with specific azobenzenes that change between amphiphilic trans form and
hydrophilic cis form upon visible and UV light exposure, respectively (Lu, et al. 2008; Pouliquen and Tribet
2006). In some formulations, both UV and NIR can be used, where single UV photon per polymer is absorbed
in the former case and two NIR photons in the latter case, thus offering flexibility in regards of triggering
equipment and light penetration depth (Jiang, et al. 2006).
Another option is to formulate temperature sensitive polymer structures and incorporate a light to heat
transforming element to the polymeric DDS. The most commonly used material is gold nanoparticle
(Gorelikov, et al. 2004; Sershen, et al. 2000) that was discussed in the previous chapter. The heat produced
by light triggering can also be used as such for photo-thermal destruction of cancer cells without more
invasive surgical procedures (Hirsch, et al. 2003).
Lipid micelles and liposomes. Liposomes constructed from photosensitive lipids can release the contents
upon light triggering overcoming the problem of inefficient drug release from traditional liposomes (Shum,
et al. 2001). Light triggered liposomes use several different mechanisms, including photo-polymerization,
photochemical triggering, photo-isomerization and photo-thermal release (Alvarez‐Lorenzo, et al. 2009).
In  photo-polymerized  liposomes,  light  of  a  suitable  wavelength  causes  reactive  dienoyl,  sorbyl  or  steryl
groups in the bilayer to form large clusters disrupting the liposomal structure and allowing the contents to
leak  out  (Bondurant,  et  al.  2001;  Spratt,  et  al.  2003).  Basically,  parts  of  the  lipid  bilayer  form  tight  raft
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structures  with  irreversible  covalent  bonds  and  pores  are  formed  on  the  surface  of  the  liposomes.
Additionally, photo-polymerizing polymers can also be incorporated into the liposomal bilayer to create light
triggered liposomes (Kostarelos, et al. 2005). The use of UV light for photo-polymerization and formation of
reactive molecules limit the applicability for therapy.
Light can also cause degradation of some lipids. Thompson et al. reported a method where liposomes were
formed by semi-synthetic lipids and photosensitizer (Thompson, et al. 1996). Visible light caused oxidation in
the alkyl chain linker and the formation of a single chain phospholipid, which in turn induces a phase
transition in the lipid bilayer. Photo-oxidation has also been used to facilitate more efficient delivery to the
cytosol  by  singlet  oxygen  mediated  disruption  of  endosomal  membranes  (Gerasimov,  et  al.  1999).  Light
induced cleavage has been used in several other liposome formulations (Chandra, et al.  2006; Zhang and
Smith 1999). Light triggered liposomes can also be used to control viscosity of injectable gels, much like the
stimuli-responsive polymers. In one study, CaCl2 was released from liposomes upon NIR light triggering, which
caused the surrounding hydrogel to cross-link consequently increasing the viscosity significantly (Zhang, et
al.  2002),  which may be used to  reduce the drug release rate.  Photochemical  triggering methods usually
induce an irreversible change in the liposome structure, which means that the mechanisms are useful for
single burst release applications, not for gradual and repeated pulses of drug release.
Photo-isomerization in liposomes can be used for light induced drug release in analogy with light switchable
polymers. Azobenzene groups can be incorporated to the phospholipids for light triggering (Bisby, et al. 2000;
Yagai, et al. 2005). Light triggering of azobenzenes alter the polarity of the lipids and subsequently the bilayer
structure is altered and the contents are released from the liposomes. Another creative application is to use
photo-isomerization in spiropyran conjugated lipid nanoparticles, where UV exposure causes a reversible
shrinkage of the particles enabling a better tissue penetration (Tong, et al. 2012).
Light induced pulsed drug release has been achieved also with thermosensitive liposomes and photo-thermal
triggering material, such as gold nanoparticles (Paasonen, et al. 2007; Paasonen, et al. 2010). In this case, the
drug release is controlled by the phase state of the lipid bilayer that will change from stable gel state to leaky
rippled and fluid state when the temperature is locally increased within the bilayer. After the light trigger is
switched off, the bilayer returns to its earlier conformation with the decrease in temperature. Drug release
can be controlled with the properties of the bilayer (particularly phase transition temperature), size and
shape of gold nanoparticles, and power and wavelength of the triggering light. In another method, coated
liposomes with a gold shell have absorption wavelengths in the visual-NIR range. Powerful laser excitation
has shown to deform the shell and the liposomal structure allowing contents release (Jin and Gao 2009). The
structural change was shown to be irreversible, therefore repeated pulsatile drug release is not possible with
this DDS.
Light triggering molecules. Some of the earliest small molecules for light triggering agent were reported in
1980 (Kano, et al. 1980). The method consisted of the previously mentioned azobenzene that undergoes
photo-isomerization when irradiated with UV light. The molecule changes from a straight trans-form into a
more curved cis-form upon exposure to light at 366 nm. Azobenzene was incorporated into a 1,2-dipalmitoyl-
sn-glycero-3-phosphocholine (DPPC) liposomal bilayer where the change in the conformation of azobenzene
increased the permeation of the contents. Interestingly, the conformational change of azobenzene can be
reversed by visible light irradiation (> 420 nm), thereby allowing reversible molecular switching (Lednev, et
al. 1998; Tsuda, et al. 2000; Willner, et al. 2001). Likewise, as with polymers and liposomes, azobenzenes can
be used with porous silica structures (Angelos, et al. 2007; Liu, et al. 2004). In those drug delivery systems,
the structure of the pores is changed and the material flow is increased upon visible light triggering.
Nevertheless, the clinical usefulness of these methods in vivo are lacking due to the low tissue penetration
and poor safety of visible and UV lights. Furthermore, the safety of azobenzenes is questionable.
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Photosensitive o-nitrobenzyl bromide has been covalently attached to a surface of silica and gold
nanoparticles for light triggered release (Agasti, et al. 2009; Wu, et al. 2008a). Various drugs were attached
to the bromide compounds. Irradiation with light (310 nm) caused cleavage of drug molecules from the
surface of the nanoparticles. Another small molecular trigger, 1,1´-dioctadecyl-3,3,3´,3´-
tetramethylindocarbocyanine perchlorate (Dil), has been included in liposomes causing drug release upon
light triggering (550 nm) (Miller, et al. 2000). In one approach, onium salts form acidic compounds via photo-
induced electron transfer bond cleavage (Saeva 1990). This can be combined with pH-sensitive
nanostructures, for example liposomes, to form light triggered DDS (Gerasimov, et al. 1997). Some molecules
produce heat upon light irradiation. One of the most interesting options is indocyanine green (ICG), which
converts IR light into heat (Chen, et al. 1995; Ma, et al. 2013; Sawa, et al. 2004). The heat might be used to
trigger drug release from thermosensitive formulations.
2.3.2.  Safety
The  DDS  should  be  safe;  otherwise  it  will  not  be  accepted  for  the  clinical  use  in  the  patients.  Gold
nanoparticles are generally well tolerated in short term (Alkilany and Murphy 2010), but their long-term
toxicology is poorly understood. The cells have limited means to deal with metal nanoparticles, therefore
accumulation of these non-biodegradable materials may pose problems in long term treatment. Although
azobenzenes have been widely studied as photo-triggering agents, they are regarded to be toxic by the FDA,
and this limits their applicability in the clinical medicine. Likewise, the o-nitrobenzyl groups and several
polymers have not been proven to be safe enough for clinical therapy (Mura, et al. 2013; Timko, et al. 2010).
In addition to the actual DDS, the safety of the triggering light should also be considered. Even though many
chemical triggering methods, like isomerization and fragmentation have good technical qualities, their
usefulness is limited by safety problems of UV light. Initial studies on light triggered liposomal DDS also
utilized UV light (Paasonen, et al. 2007; Paasonen, et al. 2010). The shorter wavelength light is more damaging
to the cells than the NIR radiation, and additionally it has poorer tissue penetration (Standard 1993). Light in
the NIR region does not cause significant heating in the application area and has been shown to be better
tolerated in ocular and other tissues (Delori, et al. 2007; Mochizuki-Oda, et al. 2002; Nagasaki and Shinkai
2007). NIR light can also penetrate several centimeters into tissues, widening the target profile. Thus, NIR
light is seen as the most promising triggering signal for light activated drug delivery systems.
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3. Aims of the study
The general objective of this thesis was to develop new liposomal formulations as potential delivery systems
for drug treatment of the posterior segment of the eye. The focus was on the liposomes that could be used
for topical and/or light triggered drug delivery to the posterior eye segment.
The specific aims of the thesis were:
1) To investigate the microfluidizing process parameters for the production of small sized liposomes
with good encapsulation efficiency of a model compound.
2) To determine the distribution of different sized liposomes in the retinal pigment epithelium and
choroid after the liposome application topically on the surface of the eye.
3) To develop and investigate visual and near-IR light triggered liposomes based on gold nanoparticles
and pH- and/or thermosensitive liposomes for triggered release.
4) To investigate the cytosolic delivery of those liposomes.
5) To develop small sized near-IR light triggered liposomes based on indocyanine green (ICG) as release
inducer for small and large molecules.
6) To understand the light-to-heat conversion of gold nanoparticles and ICG in liposomal carriers.
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4. Overview of the materials and methods
The materials and methods of this thesis are listed in table 3. The roman numerals refer to the corresponding
articles in the list of original publications. UR refers to unpublished results.
Table 3. Summary of materials and methods used in the publications and unpublished results.
THEME STUDY OBJECTIVE MATERIALS AND METHODS PUBLICATION
LIPOSOME MANUFACTURING Production of liposomes with
specific lipid composition
Thin film hydration I, III, IV, UR
Production of small sized uniform
liposomes
Microfluidizer, ultrasonication, small
pore extrusion
I, IV, UR
Enhanced cargo encapsulation Double emulsion preparation with the
microfluidizer
I
Liposomes with encapsulated gold
nanoparticles
Reverse evaporation II
LIPOSOME
CHARACTERIZATION
Particle size analysis Dynamic light scattering I, II, IV, UR
Liposome surface charge Electro-kinetic analysis I
DNA encapsulation efficiency SYBR Green assay I
Light absorbance Spectroscopy II, III, IV
Lipid phase transition Differential scanning calorimetry II, IV
Lipid layer structure Langmuir films – Brewster angle
microscopy (BAM)
II
Bilayer localization of ICG Molecular dynamics simulations IV
Light-to-heat conversion in
liposomes upon light activation
Laurdan and PEGylated CdSe QD
measured with spectroscopy
III
STABILITY Size stability of the liposomes Dynamic light scattering I, IV, UR
Contents leakage stability Spectroscopic detection of fluorescent
molecule
IV
Indocyanine green stability Spectroscopy IV
IN VITRO DRUG RELEASE Temperature induced contents
release
Controlled heating and spectroscopic
detection of the fluorescent molecule
(calcein, FITC-dextran)
II, IV, UR
Light induced contents release Laser exposure at 37 °C and
spectroscopic detection of the
fluorescent molecule (calcein, FITC-
dextran)
II, III, IV, UR
CELL STUDIES Cellular uptake of liposomes Flow cytometry - fluorescence assisted
cell sorting (ARPE-19, HUVEC)
II, UR
Cellular drug release Confocal microscopy, flow cytometry -
fluorescence assisted cell sorting
(ARPE-19, HUVEC)
II, UR
Cell toxicity Alamar blue assay (ARPE-19, HUVEC) II, UR
Annexin V assay (ARPE-19) UR
IN VIVO STUDIES Liposome distribution after topical
instillation on the eye
In vivo experiment on rats; recovery,
freezing, slicing and confocal
microscopy of the eyes
I
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5. Study I: Topical drug delivery to retinal pigment epithelium with microfluidizer
produced small liposomes
Reprinted with permission of Elsevier B.V.: Lajunen T., Hisazumi K., Kanazawa T., Okada H., Seta Y., Yliperttula
M., Urtti A., Takashima Y. (2014). Topical drug delivery to retinal pigment epithelium with microfluidizer
produced  small  liposomes.  European  Journal  of  Pharmaceutical  Sciences,  62,  23-32.
doi:10.1016/j.ejps.2014.04.018 Copyright 2014 Elsevier B.V.
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6. Study II: Light induced cytosolic drug delivery from liposomes with gold
nanoparticles
Reprinted  with  permission  of  Elsevier  B.V.:  Lajunen  T.,  Viitala  L.,  Kontturi  L.  S.,  Laaksonen  T.,  Liang  H.,
Vuorimaa-Laukkanen  E.,  Viitala  T,  Le  Guével  X,  Yliperttula  M,  Murtomäki  L  Urtti  A.  (2015).  Light  induced
cytosolic drug delivery from liposomes with gold nanoparticles. Journal of Controlled Release, 203, 85-98.
doi:10.1016/j.jconrel.2015.02.028 Copyright 2015 Elsevier B.V.
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7. Study III: Photothermally triggered Lipid Bilayer Phase Transition and Drug
Release from Gold Nanorod and Indocyanine Green Encapsulated Liposomes
Reprinted with permission of American Chemical Society: Viitala L., Pajari S., Lajunen T., Kontturi L.,
Laaksonen T., Viitala T., Urtti A., Murtomäki L. (2016). Photothermally Triggered Lipid Bilayer Phase Transition
and Drug Release from Gold Nanorod and Indocyanine Green Encapsulated Liposomes. Langmuir, 32, 4554–
4563. doi:10.1021/acs.langmuir.6b00716 Copyright 2016 American Chemical Society.
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8. Study IV: Indocyanine green-loaded liposomes for light-triggered drug release
Reprinted with permission of American Chemical Society: Lajunen T., Kontturi L., Viitala L., Róg T., Bunker A.,
Laaksonen T., Viitala T., Murtomäki L., Urtti A. (2016). Indocyanine Green-Loaded Liposomes for Light-
Triggered Drug Release. Molecular Pharmaceutics, 13, 2095–2107.
doi:10.1021/acs.molpharmaceut.6b00207 Copyright 2016 American Chemical Society.
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9. Additional unpublished results
9.1.Toxicity of near-IR laser and ICG-liposomes on ARPE-19 cell line
The safety of any DDS should be verified in toxicological studies. As a preliminary safety experiment, the
effects  of  NIR  light  exposure  and  the  ICG-liposomes  (study  IV)  on  the  viability  of  the  retinal  pigment
epithelium cell line (ARPE-19) was determined. A light source from Modulight (Tampere, Finland) was used
at a light power that released the liposome contents efficiently (9.7 W / cm2). The cells were exposed to the
light on heated (37 °C) 24 well plates for different irradiation times. In another test, the cells were incubated
with different concentrations of ICG-liposomes in the growth medium for 24 hours (37 °C). In the third
experiment, the cells were incubated with ICG-liposomes (0.3 mM) for 3 hours and then exposed to triggering
light  for  5  minutes.  The  control  cells  were  incubated  on  the  same  well  plates  without  ICG-liposomes  or
shielded from the triggering light. The condition of the cells was assessed using two fluorescence assays:
Alamar Blue test and Annexin V apoptosis assay. The former evaluates the aerobic respiration of the cells
and the latter test determines the stages of programmed cell  death with Annexin V-FITC binding at early
apoptosis and propidium iodide binding to the necrotic cells.
The triggering light did not show any toxic effects in the cells up to 20 minutes of irradiation at 37 °C (Figure
9A and 9B). The Alamar Blue viability remained unchanged compared to the control. Likewise, the Annexin V
experiment did not indicate onset of apoptosis. The negative control cells with 10 minute incubation in 35%
EtOH on the other hand showed clear apoptosis. Different concentrations of the ICG-liposomes as well as
light activated ICG-liposomes did not reduce the viability of the ARPE-19 cells (Figure 9C, 9D and 9E).
As a conclusion, the DDS and the triggering method appear to be safe for the retinal pigment epithelium cell
line. Further cell studies and eventual in vivo experiments are needed to determine the toxicity of this
method in other tissues.
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Figure 9. Toxicological measurements with ARPE-19 cells. The viability (% of the control cells) of ARPE-19 cells measured with Alamar
Blue after light exposure (A), and liposomes and light exposure (D). Apoptosis of the cells (cell number %) measured with Annexin V
kit after light exposure (B), liposome exposure (C) and liposomes with light exposure (E). The error bar represent standard deviations
(n = 3).
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9.2.Uptake of ICG-liposomes and calcein release upon light activation in ARPE-19 cells
Uptake of  ICG-liposomes into ARPE-19 cells  was  analyzed by measuring encapsulated fluorescent  calcein
using flow cytometry. The cells were incubated with 1.5 mM of ICG-liposomes for 3 hours and then exposed
to  the  triggering  light  (9.7  W  /  cm2) for 2 minutes at 37 °C. Samples without light exposure and control
samples without ICG-liposomes were also prepared.
The ICG-liposomes were efficiently taken up by ARPE-19 cells with almost 100% of the cells internalizing the
DDS (Figure 10 left  panel).  Calcein  is  a  self-quenching molecule  that  shows reduced fluorescence at  high
concentrations within the liposomes, but the signal is increased when it is released and diluted to a larger
water volume. The calcein fluorescence inside the cells was significantly higher when the cells were exposed
to the triggering light indicating that calcein is released from the liposomes (Figure 10 right panel).
Retinal pigment epithelial line (ARPE-19) efficiently internalized the ICG-liposomes and NIR light exposure to
the cells caused rapid contents release within the cells. This preliminary study gave promising results on the
applicability of ICG-liposomes for intracellular drug delivery.
Figure 10. Left panel: Cellular uptake of liposomes (% of cell that have internalized liposomes) measured with flow cytometry. Right
panel: Mean fluorescence intensity of the cells. a.u. = arbitrary units. The error bar represent standard deviations (n = 3).
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9.3.Production and characterization of small sized ICG-liposomes
In this study, our goal was to produce as small ICG-liposomes as possible with the equipment available in our
laboratory. The phospholipid composition was kept unchanged, but additional steps were included to control
the liposome size after the thin film hydration. Briefly, the hydrated liposome sample was ultrasonicated in
a heated bath sonicator (65 °C) for 15 minutes. After that, the sample was extruded first through a 100 nm
pore sized membrane and then through a 30 nm pore sized membrane (11 times). With this process, ICG-
liposomes with a diameter around 40 nm were produced (Figure 11A).
Calcein release upon light triggering from the small ICG-liposomes was slightly slower than from the normal
ICG-liposomes that released nearly all calcein in 15 seconds. The small ICG-liposomes released around 50%
of calcein in 15 seconds and almost complete cargo release was reached in 1-2 minutes (Figure 11B). The
phase transition temperatures of the lipid bilayers of two liposome formulations with different sizes were
compared. Differential scanning calorimetry results showed that the small ICG-liposomes have higher onset
temperature (43.5  °C)  for  phase transition than the normal  sized ICG-liposomes (42 °C)  (Figure 11C).  The
increased curvature of the bilayer may cause different ordering of the phospholipids in the bilayer thus
affecting the phase transition (Parthasarathy, et al. 2006). Hence, a more detailed optimization of the
phospholipid composition is needed to improve the contents release from the small sized ICG-liposomes.
The small ICG-liposomes were physically stable up to one month at the temperature range 4 – 37 °C (Figure
11D). The stability at the body temperature is due to the higher transition temperature compared to the
normal sized ICG-liposomes. The stability of the small ICG-liposomes with modified phospholipid composition
for optimal light activation remains to be studied.
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Figure 11. The diameter of small and normal sized ICG-liposomes (A). Contents release from small ICG-liposomes at 37 °C with light
exposure  times  ranging  from  5  seconds  to  2  minutes  (B)  (n  =  3).  Differential  scanning  calorimetry  at  temperatures  40  –  55  °C
(horizontal axis) of small and normal sized ICG-liposomes (C). Size stability of small ICG-liposomes in various storage temperatures
(D). The error bar represent standard deviations.
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10. Synopsis of the main results
 The main results of the publications and unpublished results are summarized in table 4.
Table 4. Summary of the main results in the publications I-IV and unpublished results.
SMALL MICROFLUIDIZER PRODUCED LIPOSOMES FOR TOPICAL DELIVERY TO RPE (PUBLICATION I)
PROCESS PARAMETERS FOR
SMALL LIPOSOMAL SIZE
Liposomes with 50 nm in diameter were produced by 15 passages through the
microfluidizer at 20,000 psi.
ENHANCED DNA
ENCAPSULATION
About 80% of DNA was encapsulated in DMPC / DMTAP liposomes of 60 nm in size
with double emulsion microfluidizer method.
IN VIVO LIPOSOME
DISTRIBUTION TO THE RPE
70 nm transferrin conjugated liposomes distributed to rat RPE after topical
instillation. 100 nm transferrin conjugated liposomes distributed to the choroid.
THE MICROFLUIDIZER OFFERS AN ATTRACTIVE OPTION FOR THE SIZE CONTROL OF LIPOSOMES. SMALL LIPOSOMES
WITH ACTIVE TARGETING MAY BE A SUITABLE DRUG DELIVERY METHOD FOR THE TREATMENT OF RPE USING TOPICAL
APPLICATION.
LIGHT TRIGGERED GOLD NANOPARTICLE ENCAPSULATING LIPOSOMES (PUBLICATION II)
TRIGGERED RELEASE Liposomal contents were released after light triggering of the gold nanoparticle
containing liposomes. The release profiles depend on the temperature, pH and NIR
light activation. Synergistic release effect of low pH and NIR light activation was
demonstrated with pH- and thermosensitive liposomes with gold nanoparticles.
CELLULAR DRUG RELEASE The optimized formulations released their calcein contents into the cytosol of
ARPE-19 and HUVEC cell lines upon light activation. Endosomal escape was not
seen in control samples without light triggering.
TOXICOLOGY Liposome formulations and the light exposure did not affect ARPE-19 and HUVEC
cell viability.
THE CONTENT RELEASE FROM THE LIPOSOMES WAS HIGHLY DEPENDENT ON TEMPERATURE, PH AND LIGHT
ACTIVATION AT NEAR INFRARED REGION. THE TRIGGERED RELEASE WAS IMPROVED COMPARED TO PREVIOUS
FORMULATIONS. THIS TECHNOLOGY MAY BE AN ATTRACTIVE OPTION FOR THE TREATMENT OF PATHOLOGICAL
CONDITIONS THAT BENEFIT FROM SPECIFIC CONTROL OF LOCATION AND TIMING OF THE DRUG RELEASE.
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LIGHT-TO-HEAT ENERGY CONVERSION OF GOLD NANOPARTICLES AND INDOCYANINE GREEN IN LIPOSOMES
(PUBLICATION III)
HEAT PRODUCTION UPON
LIGHT ACTIVATION
Both thermoprobes, laurdan and CdSe QDs, showed an increase in temperature
when gold nanoparticles or ICG were illuminated with NIR light.
LIPID PHASE TRANSITION
CAUSED BY LIGHT ACTIVATION
Light triggering of gold nanoparticles or ICG caused a bilayer phase transition to
more fluidic form in the liposomes, as indicated by a change in the laurdan
polarization.
LIPOSOMAL CONTENTS
RELEASE
A fluorescent model compound, calcein, was efficiently released upon light
triggering of either gold nanoparticles or ICG. Slightly increased contents release
was seen with ICG compared to gold nanoparticles.
CONTENTS RELEASE FROM THE LIPOSOMES IS CAUSED BY THE PHASE TRANSITION IN THE BILAYER UPON HEATING
VIA THE PHOTOTRIGGERING AGENTS, GOLD NANOPARTICLES OR ICG. THE RESULTS SHOW THE IMPORTANCE OF FINE
TUNING THE BILAYER PHASE TRANSITION AND CHOICE OF TRIGGERING MATERIALS FOR OPTIMAL DRUG RELEASE.
OPTIMIZED ICG-LIPOSOME FORMULATION FOR NIR LIGHT TRIGGERED DRUG RELEASE (PUBLICATION IV)
PHOSPOLIPID COMPOSITION
OPTIMIZATION
Liposomes consisting of DPPC / DSPC / Lyso PC / DSPE-PEG (molar ratios of 75 : 15 :
10 : 4) had suitable Tm for contents release (slightly above 37 °C) and good stability
during storage and body temperatures (4 – 37 °C).
EFFECT OF ICG
CONCENTRATION
ICG concentrations  (at  molar  ratio  of  1:200  –  1:25  relative  to  the  lipids)  did  not
affect the liposome size. Passive leakage of calcein was observed with 1:25 molar
ratio, while other formulations were stable without light induction.
MOLECULAR DYNAMICS ICG is stabilized and protected from aqueous degradation by the PEG when ICG is
mixed into the hydrolyzing solution. Conversely, ICG is located within the lipid
bilayer when it is mixed with the phospholipids.
LIPOSOMAL CONTENTS
RELEASE
Small molecular calcein and FITC-dextran macromolecules were almost completely
released from the liposomes in 15 seconds of NIR light illumination. Significant
release of both model compounds was seen with light activation periods as short
as 5 seconds.
THE ICG-LIPOSOMES CAN BE PREPARED  WITH  A  CONTROLLED SMALL SIZE. EFFICIENT NIR LIGHT TRIGGERED
CONTENTS RELEASE WAS ACHIEVED USING MATERIALS WITH REGULATORY APPROVAL. OVERALL, ICG-LIPOSOMES
ARE AN INTERESTING OPTION FOR SPATIAL AND TEMPORAL CONTROL OF DRUG RELEASE.
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CELL STUDIES WITH ICG-LIPOSOMES AND SMALL SIZED ICG-LIPOSOME CHARACTERIZATION (UNPUBLISHED
RESULTS)
TOXICOLOGY ICG-liposomes and the triggering NIR light did not reduce the viability and did not
cause apoptosis of ARPE-19 cells.
LIPOSOME UPTAKE AND
CONTENTS RELEASE IN CELLS
ICG-liposomes were efficiently taken up into the cells (over 90% of cells
internalized liposomes). Light triggering caused contents release within the cells
that was detected based on the increase in fluorescence.
CHARACTERIZATION OF 40 NM
SIZED ICG-LIPOSOMES
Combination of ultrasonication and extrusion through 100 nm and 30 nm
polycarbonate membranes produced ICG-liposomes with a diameter of 40 nm.
These liposomes were physically stable at least for 1 month. Calcein release upon
light triggering was slower in 40 nm liposomes than in the 100 nm ICG-liposomes.
The lipid phase transition of 40 nm sized liposomes was at higher temperature
compared to 100 nm ICG-liposomes.
ICG-LIPOSOMES AND TRIGGERING LIGHT WERE FOUND TO BE  SAFE  FOR ARPE-19  CELL  LINE  AND INTRACELLULAR
CONTENTS RELEASE WAS OBSERVED UPON LIGHT ILLUMINATION. ICG-LIPOSOMES CAN BE PREPARED AT VERY SMALL
SIZE  WHILE  RETAINING  THEIR  FUNCTIONALITY.  THIS  IS  IMPORTANT  FOR  DRUG  DELIVERY  TO  MANY  TISSUES.  SIZE
REDUCTION AFFECTS THE LIPID PHASE TRANSITION, SO OPTIMIZATION OF LIPID COMPOSITION FOR SMALL ICG-
LIPOSOMES IS NEEDED.
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11. Discussion and future prospects
As the focus of new therapeutic compounds continues to transfer from traditional small molecular drugs to
biologicals, the need for efficient drug delivery methods increases. Liposomes have for a long time been used
for  drug  delivery  and  still  new  aspects  of  liposomes  are  widely  studied  (Figure  12).  Despite  their  good
properties, the unmodified liposomes lack the spatial and temporal control of drug release. Light activation
is one of the most promising approaches to solve this problem. After the pioneering work in the 1980’s to
2000, light activated drug delivery has gained interest of the scientific community as indicated by the sharp
increase in the number of publications (Figure 12). The field is still relatively young, thus offering several new
possibilities for discovery and innovations. This thesis focuses on combining light activated release with the
liposome technology. The main therapeutic focus is the challenging drug delivery to the posterior segment
of the eye.
Figure 12. Yearly number of publications (research articles and review articles) indexed in Scopus database on 19th of April 2016 with
search terms “liposome” (open circles) and “light activation AND drug release” (solid triangles). Timescale from 1960 to 2014 is
presented.
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11.1. Microfluidizer for liposome production
Liposome size has traditionally been controlled by sonication or extrusion through a polycarbonate
membrane (Ulrich 2002). These methods are useful, but have some caveats, e.g. high polydispersity in case
of the sonication, and somewhat limited scale-up potential of the extrusion. Microfluidizer on the other hand
produces  monodisperse  liposomes  and  this  method  is  scalable  from  the  laboratory  scale  to  commercial
production volumes. The technology has already been adopted by food industry (Augustin and Sanguansri
2009) and should also be applicable in pharmaceutical production (Sorgi and Huang 1996; Wagner and
Vorauer-Uhl 2011).
In study I, the microfluidizer process parameters for liposome preparation were elucidated and optimized.
We used M-110P Microfluidizer that is designed for processing of large volumes of liquids. The minimum
sample volume is 50 mL and the upper limit is basically only limited by the size of the product inlet reservoir.
The microfluidizer enabled the production of different liposome sizes by changing the operating settings: the
size reduction of liposomes was proportional to the increase in pressure. The effect has also been verified in
other microfluidizer models (Barnadas-Rodrıǵuez and Sabés 2001). The benefit of the device is the ability to
produce liposome lots with various sizes without changing the equipment. The M-110P microfluidizer was
also compared to a laboratory scale LV-1 model that can process samples as small as 1 mL. Unfortunately, a
similar  Y-type interaction chamber used in  the M-110P model  was not  available  for  the LV-1 model  and,
therefore, less efficient Z-type chamber was used. Thus, even with the same process parameters (pressure
and passage numbers), the LV-1 produced larger liposomes than M-110P. Nevertheless, the LV-1 should
achieve similar results with a similar Y-type interaction chamber.
Often, encapsulation efficiency of hydrophilic drugs into liposomes is low with traditional preparation
methods (e.g. thin film hydration and extrusion). This is also true in case of the microfluidizer because the
drug concentration in the liposomes’ inner aqueous space would be equal with the external concentration,
unless active encapsulation methods are used (e.g. remote loading by ammonium sulfate gradient) (Bolotin,
et al. 1994). Unfortunately, these methods are not widely applicable, since they have specific requirements
related to the encapsulated drug. In study I,  a more robust method for high encapsulation efficiency was
developed. The basis of the method is a water / organic / water double emulsion, where the internal water
phase is isolated from the outer bulk aqueous solution. This method has achieved high encapsulation
efficiencies by high speed mixing of the double emulsion (Nii, et al. 2003). The method in study I utilized the
microfluidizer for smaller liposomal size and polydispersity. It was shown to provide encapsulation
efficiencies of about 80% for liposomes with significantly reduced size compared to Nii et al. (i.e. 60 nm vs.
400 nm and larger). A smaller liposome size is vital for drug delivery to many target sites, such as the RPE
(Guymer, et al. 2004). In the case of the microfluidized double emulsion liposomes, the hydrocarbon chain
lengths of the phospholipids were found to be an important property for determining the final particle size
with shorter chains resulting in smaller liposomes.
The importance of liposomal size in drug delivery to the posterior segment of the eye was studied by topical
instillation on the rat eyes. The tissue samples were collected 5 and 15 minutes after eye drop application.
Liposomes were seen to deposit to the posterior tissues in a few minutes. Such a fast distribution indicated
a blood circulation path instead of passive permeation through the layers of the eye. Smaller 70 nm liposomes
with  active  targeting  ligands  distributed  to  the  RPE,  but  larger  100  nm  liposomes  remained  in  choroidal
endothelium even with similar active targeting properties. However, previous reports have shown
distribution of larger liposomes to neural retina and ganglion cells after topical instillation (Davis, et al. 2014;
Masuda, et al.  1996). Overall,  the study showed feasibility of the microfluidizer as a versatile method for
liposome preparation. Also, the importance of active targeting and correct carrier size was qualitatively
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demonstrated. This may enable the treatment of RPE with drug compounds that normally are not distributed
to the target tissue in therapeutically effective concentrations.
11.2. Time and location control of drug release: Light activated liposomes with gold
nanoparticles
Distribution of drug carrier to the correct tissue may not be adequate for an effective therapy. The target
sites of several compounds are located intracellularly and among these drugs are many biologicals like siRNA,
DNA and some proteins. However, in order to exert the therapeutic effects intracellularly, the drugs need to
reach the cytosol and other organelles depending on the site of action (e.g. nucleus, mitochondria or
endoplasmic reticulum). Large molecules do not permeate across the plasma membrane and, hence, they
need to be trafficked and released into the cells with a suitable carrier. Nanoparticles enter the cells usually
via endocytosis, but the material is usually transferred to the lysosomes for degradation (Ulrich 2002). The
low endosomal pH has been utilized for enhancement of endosomal escape (Han, et al.  2012; Kim, et al.
2009;  Simões,  et  al.  2004;  Slepushkin,  et  al.  1997),  but  this  method  lacks  the  specificity  of  drug  release
location at the diseased area of the tissue. Also, the time point of drug release cannot be externally controlled.
Study II focused on light activation as a means to achieve better control over drug release from the liposomes.
The proof-of-principle of light activated liposomes with gold nanoparticles has been reported previously
(Paasonen, et al. 2007; Paasonen, et al. 2010). Early research in the field utilized UV light for release activation,
but the NIR light shows advantages, such as better tissue penetration and safety (Delori, et al. 2007; Standard
1993). In principle, light offers a spatially and temporally focused signal and a lot of possibilities for
optimization (e.g. pulse length and shape, intensity, wavelength). Modern fiber optics and good tissue
penetration may enable treatment of deeper tissues with minimal invasiveness.
In study II, gold nanorods and gold nanostars were encapsulated into thermosensitive liposomes. Irradiation
of these gold nanoparticles with light produces heat via the surface plasmon resonance phenomenon (Jain,
et al. 2006). The nanorods absorb light energy at visual wavelength and nanostars at NIR wavelengths,
respectively. Furthermore, a novel liposome formulation that combined thermosensitivity with pH-sensitivity
was developed. This would, in theory, enable even more focused drug release only in the acidic intracellular
compartments. Stabilizing domains consisting of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)
and cholesteryl hemisuccinate (CHEMS) destabilized at endosomal ph 5. This sensitized the formulation for
light induced drug release. On the other hand, the liposomes outside cells in neutral conditions (pH 7.4)
would not be sensitive to the triggering light signal.
The results showed efficient calcein release after liposome exposure to the triggering signals. Small molecular
fluorescent calcein was released in vitro and in two cell lines upon light triggering. The triggering light and
formulation were safe to the tested cell lines. The pH- and thermosensitive liposomes showed interesting
results lipid layer characterization studies. The Langmuir film – BAM data indicated a formation of domains
or lipid rafts in the layer at low pH conditions, instead of homogenous mixing of the different phospholipids.
This phenomena was supported by the calorimetric measurements that showed multiple transition peaks
instead of the typical single peak. The increased fluidity of liposomal bilayer may enhance fusion of the
liposomes with the endosomal wall, thus enabling contents escape to the cytosol.
Due to the highly localized heating by light activation, true temperature in the liposomal bilayer is impossible
to measure by traditional thermometers. Previously SAXS has been used to measure the phase changes in
light activated liposomes with gold nanoparticles and the results indicated that light activation and increased
temperature induce similar changes in the lipid bilayers (Paasonen, et al. 2010). However, SAXS did not allow
direct determination of temperature in the bilayers. In study III, two nanosized thermometers, laurdan and
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CdSe QDs, were utilized to measure the local temperature change in the liposomes and to study the bilayer
fluidity. Macroscale methods for the lipid film studies, such as Langmuir film – BAM measurements, could
not be used in the experiments on light triggering of the liposomes. Therefore, the nanosized thermometers
provided a dual temperature readouts: laurdan in the lipid bilayer and the QDs in the aqueous bulk solution.
A change in laurdan polarity also provides information about the bilayer phase transition during the
temperature increase. Both, laurdan in the lipid bilayer and CdSe QDs in the bulk solution, showed higher
temperatures when gold nanorod concentration was increased. 0.4 nM and 2.0 nM of gold nanorods showed
20.5 °C  and 21.5  °C  increases  in  temperature,  respectively.  The effect  was not  linear  due to  pronounced
heating at the sample surface compared to deeper portions of the sample, which has also been shown in a
previous report (Jang, et al. 2011). The two nanothermometers showed similar temperature changes
indicating a rapid distribution of heat in the samples. This heat production was found to effectively release
calcein from simple DPPC liposomes with encapsulated gold nanorods.
A few critical problems remain even though the gold nanoparticles are functional in the light triggered drug
release from the liposomes. Firstly, the absorbance of the gold nanoparticles is related to their shape and
size, with larger particles absorbing at longer wavelengths. Obviously, the carrier must be larger than the
gold nanoparticles. Thus, the liposomes were formulated to a size range around 150 – 200 nm, but this size
is too large for carrier permeation from choroidal blood vessels to the retinal pigment epithelium. They may
be still suitable for intravitreal injections, since they probably diffuse well in the vitreous (Xu, et al. 2013).
However, their ability to pass through the inner limiting membrane in the retina is uncertain (Pitkänen, et al.
2004). Smaller liposomes would be advantageous also in terms of distribution to the tumors (Nagayasu, et
al.  1999). Secondly, the long-term safety of gold nanoparticles is not known. The inert gold nanoparticles
generally do not elicit acute toxicity in the cells and in vivo, but only short term studies of toxicology of gold
nanoparticles  have  been  reported  so  far  (Alkilany  and  Murphy  2010).  FDA  guidelines  instruct  that
pharmaceuticals should be eliminated from the body in order to avoid accumulation, thus reducing the
possible toxicity. Gold nanoparticles with diameters larger than 5.5 nm are not filtered through the kidneys
into urine (Choi, et al. 2007), and their high chemical stability causes them to accumulate in the spleen and
liver  (De Jong,  et  al.  2008).  This  may have serious  long term adverse effects.  Also,  their  distribution and
elimination in the eye are unknown.
11.3. ICG-liposomes as light triggered DDS
In study III, the heat production of indocyanine green (ICG) was compared with gold nanorods as triggering
material. Like the nanorods, ICG absorbs NIR light at around 800 nm and converts the light energy to heat. In
theory, liposomes with ICG do not have the similar limits as the liposomes with larger gold nanoparticles.
Furthermore, FDA has already approved ICG for human imaging use and thus it should be safe. Study III
showed that ICG decomposed during the light triggering and, therefore, the heating effect and induction of
drug release will stop when all ICG has decomposed. Unfortunately, the detection equipment had a maximum
time resolution of 1 min, and it did not allow determination of faster changes in temperature. ICG produced
comparable heating with the gold nanoparticles. The heat conversion time could be extended with the
addition of a single-oxygen quencher, sodium ascorbate, but this may not be necessary for the functionality
of  the  DDS  if  the  drug  release  is  faster  than  the  decomposition  of  the  ICG.  Calcein  release  from  DPPC
liposomes was also achieved with light triggering of ICG with slightly higher efficiency compared to the gold
nanoparticles. The drug release data should not be directly compared, because the concentrations of the
light converting materials were not optimized. However, as a proof-of-concept, the nanothermometer
studies  showed  that  both  triggering  materials,  gold  nanorods  and  ICG,  increase  the  temperature  of  the
liposomes over the phase transition temperature. The light signal alone did not have the same effect. The
temperature dissipates quickly and the heating effect is significantly reduced in relation to the distance from
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the triggering agent (Potdar and Sammalkorpi 2015), and thus the heating of the surrounding tissue is should
not be significant. The nanothermometer method may be useful in evaluating the heating capabilities and
thermal safety profile of various triggering materials.
Study IV describes the development of a new light triggering formulation based on the idea of
thermosensitive liposomes with ICG. The phospholipid composition was optimized for sensitive photo-
thermal drug release and adequate stability. Molecular dynamics study suggests that the location of ICG in
lipid bilayers depends on the preparation method of the liposomes. Previous studies have speculated that
amphiphilic ICG would embed itself into the lipid bilayer (Kraft and Ho 2014) and this is indeed the case when
ICG is  mixed directly  with  the lipids.  However,  if  PEG is  present  in  the liposome formulation,  then ICG is
wrapped by the PEG chains when added to the aqueous solution and does not enter the lipid bilayer. This
simulation data was supported by the phase analysis of ICG-liposomes: no effects on the phase transition
were seen with increasing ICG concentrations. According to our ongoing experiments, when ICG is mixed into
an organic phase with lipids including PEG during manufacturing, it partitions between the lipid bilayer and
PEG coating (data not shown). The ratio of partitioning is currently being studied. Importantly, the molecular
size of ICG enabled the preparation of very small liposomes (around 60 nm) solving the size problem of the
gold containing liposomes. Smaller ICG-liposomes should be able distribute efficiently within the vitreous,
retinal layers and choroid (including the passage thought fenestrations in the vessels) (Guymer, et al. 2004;
Xu, et al. 2013).
The ICG-liposomes released their contents in 15 seconds upon light activation. The fast rate of drug release
indicates that the decomposition of ICG shown in study III does not hamper its light activated functionality.
In contrast, the decomposition of the light triggering material may be beneficial for the safety of the DDS. As
the heat production ends with the decomposition of the ICG, the tissues and cells are not unnecessarily
heated even if light irradiation is continued. This is in contrast with photodynamic therapy, where the
objective is photothermal destruction of the cells (Dolmans, et al. 2003). Generally, the extended heating
might cause localized damage in the target cells in case of stable light triggering materials, like gold
nanoparticles. The singlet oxygen decomposition products of ICG have been shown to reduce the viability of
cells, but the concentrations were higher than in our DDS (Engel, et al. 2008), and RPE cells are particularly
efficient in dealing with oxidative stress (Cai, et al. 2000). In addition to calcein, larger macromolecular model
compounds up to a size of 20 kDa were efficiently released from the ICG-liposomes upon light triggering. This
is a vital quality in controlled release of biologics. This may offer a potential solution for the important
intracellular delivery of DNA and oligonucleotides.
The preliminary toxicity experiments, described in the unpublished results section, showed that the ICG-
liposomes and the triggering NIR light did not reduce the viability of retinal pigment epithelial cells (ARPE-
19).  This  conclusion  was  confirmed  with  three  different  markers  of  cell  death.  However,  toxicological
evaluation in one cell line is only the first step in understanding the toxicity profile of the DDS. The results
showed that at the triggering light is well tolerated even during long exposures in pigment epithelia, even
though the exposed light power was higher than the current limits of light irradiation to eyes (Delori, et al.
2007). The posterior segment of the eye has many cellular layers that are sensitive to the light, especially the
light sensing rods and cones of neural retina. Nevertheless, the power and duration of the triggering light
may be reduced by optimizing the drug release sensitivity of the DDS. Unfortunately, artificial cultivation of
these cells  in  correct  conformation is  not  a  trivial  matter,  and thus  the damage to  these cells  should be
evaluated by in vivo experiments (Valjakka, et al. 2007). Furthermore, only acute cellular toxicology has been
determined. The long term evaluation of ICG-liposomes is needed to prove their safety.
Cell  uptake of ICG-liposomes was excellent in the cultured ARPE-19 cells.  This result is comparable to the
thermosensitive liposomes with gold nanoparticles in study II. NIR light triggering of ICG-liposomes caused
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similar contents release as the gold nanoparticle liposomes in the cells. The experiment with ICG-liposomes
showed the release of calcein in the cells, but did not indicate the intracellular location of the release (e.g.
endosomes, cytosol). Cytosolic drug release was shown with the gold nanoparticle based liposomes in the
study II, and efficiency of cytosolic drug release is currently being researched with ICG-liposomes. One of the
most distinctive advantages of ICG as a light triggering material, is the flexibility of controlling the size of the
liposomes. The unpublished results showed that it is possible to produce ICG containing liposomes as small
as 40 nm with retained light triggering functionality. This quality increases robustness of the DDS enabling
drug delivery to a wider selection of target tissues. Size reduction even further is theoretically impossible, as
the volume of the internal aqueous space decreases. A phospholipid bilayer is generally 5 nm in thickness
(Balgavý, et al. 2001) and thus it is not possible to form very small stable liposomal structures because of the
stress induced by the increased curvature and lack of space for the hydrocarbon chains within the bilayer.
Manufacturing of ICG-micelles of smaller size (< 20 nm) consisting of single layer lipid spheres may in theory
be possible, but then the drug cargo is limited to lipophilic compounds.
The fluorescence of ICG gives an opportunity for imaging and tracking of the DDS in vivo. Low laser power
should be used for imaging purposes in order to prevent drug release activation before the DDS has reached
the target site. The ICG based imaging may enable detection of DDS distribution to different layers in the
posterior segment of the eye, for example. When the drug carrier is detected at the target cells, the localized
triggering laser signal is applied.
11.4. Considerations for the future
Many aspects of the light triggered liposomes still remain to be studied in the future. So far we have shown
the proof-of-principle in vitro and optimized the formulation for light activated release.  It is still a challenge
to translate the technology to therapeutic setting with small molecular drugs or biologics. The safety of the
system in systemic or local administration needs to be verified in animal experiments and humans.
Additionally, the in vivo distribution of the DDS and in vivo release with light induction need to be studied.
Depending on the target site, different routes of drug administration can be used, e.g. intravenous or
intravitreal injections, inhalation and topical delivery methods. Different challenges and requirements apply
to each application route and the in vivo distribution must be evaluated separately for each case.
In regards to eye medication, light activated liposomes offer many attractive properties. The formulation
does not limit the possible administration route, because liposomes can be applied topically,
suprachoroidally and intravitreally. The DDS may enable increased bioavailability for challenging drugs
including several macromolecules. Furthermore, the light activation pinpoints the drug effect to the diseased
tissue, thus drugs with generally poor safety profile may be useful again. Increased treatment efficiency
would extend the dosing interval thus reducing the need for uncomfortable and costly procedures to the
patient’s eyes. Light triggered liposomes might be a so called “enabling technology”, which permits treatment
with otherwise unusable drugs for the difficult diseases in eyes.
After adequate DDS concentrations at the target site are measured, the actual therapeutic efficacy of the
carrier needs to be studied with applicable disease models and finally in patients. Careful selection of the
potential pathological conditions is vital. There should be a valid reason and clear advantage for the use of
the DDS, such as unsatisfactory efficacy or considerable adverse effects with the current treatment protocols.
The new DDS should be able to reach the target and in case of light triggered liposomes, the target site has
to be effectively stimulated with NIR-light. Extensive comparisons to current state-of-the-art treatments are
required to prove the advantage of the drug administration in light triggered DDS.
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The surface of liposomal drug delivery systems can be modified for targeting and prolonged residence time
in the compartment of administration (e.g. plasma, vitreous cavity) (Torchilin 2012). In the current form, the
ICG-liposomes do not have any active targeting mechanism, but they include PEG moieties for prolonged
residence time. PEG coating can be used for the attachment of targeting ligands, as well as for other possible
modifications, such as inclusion of cell penetrating peptides for improved cellular uptake. Addition of pH-
sensitivity is one of the development possibilities for ICG-liposomes. This requires alterations of the bilayer
composition and thus great care should be taken not to hamper the light triggering properties of the DDS.
These modifications could result in improved cytosolic drug delivery and higher selectivity of release, i.e.
faster drug release in the acidic cellular compartments compared to the neutral extracellular space.
Realistically, there are many hurdles before light activated liposomes could reach the clinical use. For
example, attachment of several functions to the DDS imposes problems in the industrial production.
Generally, the production cost increases and reproducibility decreases with the number of different
compounds in the formulation. The first target for reducing the number of compounds would be the
compounds that have similar functions in the system, for example two neutral phospholipids, DPPC and DSPC
with different phase transition temperatures. Perhaps, similar properties would be achievable with one
bilayer component.
Commercial viability of any system depends on the market situation and pricing of the product. How many
people are suffering from a particular disease? Are there already satisfactory lower cost medicines for the
condition? Light activated liposomes may be suitable for the treatment of cancer and serious ocular diseases.
As described in the introduction, the treatment of these conditions needs improvements in efficiency, safety
or patient comfort. Furthermore, as the population in the western world and emerging markets continues to
shift towards the elderly demographics, the need for treatments will increase. Likewise, we are on the eve of
the new age of biologicals (including gene medicines) and this will further emphasize the need for controlled
drug delivery systems.
90
12. Conclusions
In this thesis, new liposomal drug delivery systems were investigated. The main conclusions of the studies
are divided and summarized as follows:
1) The microfluidizer method is capable of producing large sample batches of liposomes with very
small  uniform particle  size  (<  80 nm).  Small  liposomes with  transferrin  reached the RPE after
topical eye drop instillation at detectable quantity. Larger particles do not permeate to the RPE
after topical delivery. The microfluidizer method is an attractive option to manufacture small
liposomes that may enable treatment of retinal diseases with topical eye drops.
2) Light activated and pH-sensitive liposomes with encapsulated gold nanoparticles were
formulated and optimized. After cellular uptake the liposomes released their fluorescent
contents to the cytosol upon light activation. The formulations and light activation were safe in
two cultured cell lines. These results suggest that a site-specific and light induced drug release in
the  target  cells  may  be  possible  with  the  light  activated  liposomes,  but  the  size  of  these
liposomes may limit their usefulness in drug delivery.
3) Two triggering materials light induced drug release, gold nanorods and indocyanine green, were
evaluated as light-to-heat converters using two nanothermoprobes, laurdan and CdSe QD. Upon
NIR light irradiation both materials resulted in liposome heating, phase transition in the lipid
bilayers and marker leakage from the liposomes. The method is applicable in mechanistic studies
of light inducible nanosystems.
4) ICG-liposomes for light triggered drug release were optimized in terms of lipid composition and
quantity  of  ICG.  The  ICG-liposomes  showed  fast  contents  release  in  seconds  upon  NIR  light
triggering. Almost complete release of small and large encapsulated fluorescence probes was
observed.  Small  functional  ICG-liposomes  (40  and  100  nm)  were  formulated  at  narrow  size
distribution. These liposomes and activating light signal were safe for retinal pigment epithelial
cells in culture. Molecular dynamics simulations informed us about the localization of ICG in the
liposomes. Overall, ICG-liposomes have many advantageous properties that warrant further
studies on their applicability for light triggered drug release at specific diseases targets, for
example in the posterior eye segment.
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